

Article

Acetic Acid Mediated for One-Pot Synthesis of Novel Pyrazolyl *s*-Triazine Derivatives for the Targeted Therapy of Triple-Negative Breast Tumor Cells (MDA-MB-231) *via* EGFR/PI3K/AKT/mTOR Signaling Cascades

Ihab Shawish ^{1,2}, Assem Barakat ^{2,*}, Ali Aldalbahi ², Walhan Alshaer ³, Fadwa Daoud ³, Dana A. Alqudah ³, Mazhar Al Zoubi ⁴, Ma'mon M. Hatmal ⁵, Mohamed S. Nafie ⁶, Matti Haukka ⁷, Anamika Sharma ^{8,9}, Beatriz G. de la Torre ^{8,9}, Fernando Albericio ^{9,10,11,*} and Ayman El-Faham ^{12,*}

- ¹ Department of Math and Sciences, College of Humanities and Sciences, Prince Sultan University, P.O. Box 66833, Riyadh 11586, Saudi Arabia; ishawish@psu.edu.sa
- ² Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia; aaldalbahi@ksu.edu.sa
- ³ Cell Therapy Center, The University of Jordan, Amman 11942, Jordan; walhanjordan@yahoo.com (W.A.); fadwadaoud22@gmail.com (F.D.); pharmd.dana.alqudah@gmail.com (D.A.A.)
- ⁴ Department of Basic Medical Sciences, Faculty of Sciences, Yarmouk University, Irbid 21163, Jordan; mszoubi@yu.edu.jo
- ⁵ Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, The Hashemite University, P.O. Box 330127, Zarqa 13133, Jordan; mamon@hu.edu.jo
- ⁶ Department of Chemistry, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt; mohamed_nafie@science.suez.edu.eg
- ⁷ Department of Chemistry, University of Jyväskylä, P.O. Box 35, FI-40014 Jyväskylä, Finland; matti.o.haukka@jyu.fi
- ⁸ KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa; anamika.aug14@gmail.com (A.S.); garciadelatorreb@ukzn.ac.za (B.G.d.I.T.)
- ⁹ Peptide Science Laboratory, School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa
- ¹⁰ CIBER-BBN (Networking Centre on Bioengineering, Biomaterials and Nanomedicine) and Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain
- ¹¹ Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), 08034 Barcelona, Spain
- ¹² Chemistry Department, Faculty of Science, Alexandria University, P.O. Box 426, Ibrahimia, Alexandria 12321, Egypt
- * Correspondence: ambarakat@ksu.edu.sa (A.B.); albericio@ukzn.ac.za (F.A.); ayman.elfaham@alexu.edu.eg or aymanel_faham@hotmail.com (A.E.-F.)



Citation: Shawish, I.; Barakat, A.; Aldalbahi, A.; Alshaer, W.; Daoud, F.; Alqudah, D.A.; Al Zoubi, M.; Hatmal, M.M.; Nafie, M.S.; Haukka, M.; et al. Acetic Acid Mediated for One-Pot Synthesis of Novel Pyrazolyl *s*-Triazine Derivatives for the Targeted Therapy of Triple-Negative Breast Tumor Cells (MDA-MB-231) *via* EGFR/PI3K/AKT/mTOR Signaling Cascades. *Pharmaceutics* **2022**, *14*, 1558. <https://doi.org/10.3390/pharmaceutics14081558>

Academic Editor: Sudip K. Das

Received: 21 June 2022

Accepted: 22 July 2022

Published: 27 July 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Here, we described the synthesis of novel pyrazole-*s*-triazine derivatives via an easy one-pot procedure for the reaction of β -dicarbonyl compounds (ethylacetoacetate, 5,5-dimethyl-1,3-cyclohexadione or 1,3-cyclohexadionone) with *N,N*-dimethylformamide dimethylacetal, followed by addition of 2-hydrazinyl-4,6-disubstituted-*s*-triazine either in ethanol-acetic acid or neat acetic acid to afford a novel pyrazole and pyrazole-fused cycloalkanone systems. The synthetic protocol proved to be efficient, with a shorter reaction time and high chemical yield with broad substrates. The new pyrazolyl-*s*-triazine derivatives were tested against the following cell lines: MCF-7 (breast cancer); MDA-MB-231 (triple-negative breast cancer); U-87 MG (glioblastoma); A549 (non-small cell lung cancer); PANC-1 (pancreatic cancer); and human dermal fibroblasts (HDFs). The cell viability assay revealed that most of the *s*-triazine compounds induced cytotoxicity in all the cell lines tested. However, compounds **7d**, **7f** and **7c**, which all have a piperidine or morpholine moiety with one aniline ring or two aniline rings in their structures, were the most effective. Compounds **7f** and **7d** showed potent EGFR inhibitory activity with IC₅₀ values of 59.24 and 70.3 nM, respectively, compared to Tamoxifen (IC₅₀ value of 69.1 nM). Compound **7c** exhibited moderate activity, with IC₅₀ values of 81.6 nM. Interestingly, hybrids **7d** and **7f** exerted remarkable PI3K/AKT/mTOR inhibitory activity with 0.66/0.82/0.80 and 0.35/0.56/0.66-fold, respectively, by inhibiting their concentrations to 4.39,

37.3, and 69.3 ng/mL in the 7d-treatment, and to 2.39, 25.34 and 57.6 ng/mL in the 7f-treatment compared to the untreated control.

Keywords: one-pot synthesis; DMF-DMA; pyrazolyl-*s*-triazine; anticancer profile; EGFR/PI3K/AKT/mTOR; apoptosis

1. Introduction

Pyrazole derivatives are a highly relevant class of heterocyclic compounds as they are vital substructures in a variety of compounds with important biological properties [1–5]. They have a wide spectrum of activities, including antimicrobial [6–8], anti-inflammatory [9], antiparasitic [10], antidepressant [11], antiviral [12], antifungal [13], and antitumor [14,15] activity. Moreover, the pyrazole nucleus is the core unit in numerous FDA-approved pharmaceutical drugs such as celecoxib (Celebrex) [16], sildenafil (Viagra) [17], and rimonabant (Acomplia) [18].


Given the excellent bioactivity and wide range of applications of pyrazole derivatives, many studies have addressed their synthesis and bioactivities [19,20]. Furthermore, the methodology for the synthesis of these derivatives has been summarized in several reviews [7,21–23].

Enaminediones are widely used to generate polysubstituted pyrazoles [20,24–26]. To innovate pharmaceutically relevant pyrazoles, the research community has been attracted to the capacity of enaminediones and 1,2- and 1,3-dinucleophiles to construct diverse heterocycles [2–5].


On the other hand, many *s*-triazine (1,3,5-triazine) derivatives show a wide range of biological activity [27–33]. Thus, the synthesis and evaluation of *s*-triazine derivatives coupled with a pyrazolyl ring is a key endeavor in the field. *s*-triazines with the pyrazolyl fragment in their structure can be synthesized by cyclotrimerization of aromatic nitriles [34] or from cyanuric chloride by substitution of the first or second chlorine atom by the aromatic amines containing the pyrazolyl fragment [35]. Ayyangar et al. prepared *s*-triazinylpyrazoles by reacting hydrazinyl-*s*-triazines with 3-iminobutyronitrile and acetoacetic ester [36]. Later, Mikhaylichenko et al. reported the synthesis of 1,3,5-triazine pyrazole derivatives using quaternary amine salts [37].

Recently, we described the synthesis of pyrazole-*s*-triazine derivatives by direct reaction with β -diketone, using triethylamine as a catalyst or using HClO₄ in an aqueous medium [38,39]. In the present work, we describe a one-pot method for the synthesis of pyrazole and fused pyrazole-*s*-triazine derivatives in the presence of acetic acid *via* the formation of the enaminedione derivatives of β -diketone.

The search for new compounds with therapeutic efficacy is a major focus in medicinal chemistry. However, the latent progress of resistance or tolerance to these compounds over time, particularly in the context of the treatment of diseases such as cancer, severely limits their medical use. Many representative examples reported for cancer treatment, either approved for human use or in late-stage clinical trials, contain the 1,3,5-triazine (*s*-triazine) moiety. In 1990, the US FDA approved Hexalen (Altretamine) (Figure 1, compound I), as an example of targeted therapy for ovarian cancer [40]. First authorized in 2017 by the US-FDA, Enasidenib (Idhifa, compound II) is another commercial drug based on the *s*-triazine scaffold and it is used to treat IDH2-positive acute leukemia [41]. Indeed, Gedatolisib was reported as first-in-class to treat breast cancer via the PI3K/mTOR inhibitor (Figure 1, compound III) [42]. Several molecules have been reported to be tethered to the *s*-triazine motif, such as targeted EGFR-TK inhibitors IV [43] and V [44], VI ZSTK474 (as PI3K/MEK dual inhibitors) [45], and Bimiralisib (PQR309) (compound VII) [46–48]. Moreover, VIII [49] also shows anti-cancer efficacy as a dual inhibitor of PI3K/mTOR (Figure 1). More recently, compound IX possessed EGFR/PI3K/AKT/mTOR signaling cascades inhibitor [50] (Figure 1).



Synthetic Approach



Most active compounds targeted therapy of MDA-MB-231 via EGFR/PI3K/AKT/mTOR signaling cascades




Figure 1. Selected *s*-triazine as an anticancer agent targeting the EGFR/PI3K/AKT/mTOR cascades and our designed compounds.

In the framework of our ongoing project based on the use of *s*-triazine as a scaffold for the development of novel agents for cancer treatment [38,39], we tested a new series of pyrazolyl-*s*-triazine derivatives against MCF-7, MDA-MB-231, U-87 MG, A549, PANC-1, and HDF cell lines. To better understand the potential mechanism of action of these compounds in human cancer cells, we also conducted an EGFR enzymatic assay and evaluated the PI3K/AKT/mTOR downstream signaling pathway. Finally, a molecular docking study targeting the EGFR/PI3K/AKT/mTOR cascades was conducted.

2. Materials and Methods

2.1. Chemistry

2.1.1. Materials and Methods

All reagents and solvents were purchased from commercial suppliers and used without further purification. The reaction was followed up and checks of the purity were done using TLC on silica gel-protected aluminum sheets (Type 60 GF254, Merck, Darmstadt, Germany). Melting points were recorded on a Mel-Temp Apparatus (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) in an open capillary and are uncorrected. Fourier transform infrared spectroscopy (FTIR) was conducted on a Shimadzu 8201 PC FTIR spectrophotometer (Shimadzu, Ltd., Kyoto, Japan). ^1H NMR and ^{13}C NMR spectra were recorded on a JEOL 400 MHz spectrometer (JEOL, Ltd., Tokyo, Japan), and chemical shift (δ) values were expressed in ppm. Elemental analyses were performed on a Perkin-Elmer 2400 elemental analyzer (PerkinElmer, Inc., Waltham, MA, USA). High resolution mass spectrometry (HRMS) was performed using a Bruker ESI-QTOF mass spectrometer (Bruker, Billerica, MA, USA) in positive-ion mode.

General Procedure for the Synthesis of 2-Hydrazino-6-Substituted *s*-Triazine Derivatives, **3a–l**

A solution of amine (20 mmol) in acetone (50 mL) was added dropwise over 15 min to a solution of cyanuric chloride **1** (20 mmol) in acetone (50 mL) at 0–5 °C. After complete addition, an aqueous solution of NaHCO_3 (22 mmol equiv.) in water (50 mL) was added dropwise (10 min) at the same temperature. The reaction mixture was then stirred at 0–5 °C for 2 h. After completion of the reaction and disappearance of the starting materials (TLC, ethyl acetate/hexane 2:8), the second nucleophile (20 mmol) in acetone (50 mL) was added at the same temperature, followed by addition of an aqueous solution of NaHCO_3 (22 mmol equiv.) in water (50 mL). The reaction mixture was stirred at 0 °C for 1 h and then at rt overnight. Excess distilled water was added and the precipitates of products **2a–l** (Scheme 1) were collected by filtration, washed with water (2×20 mL), and dried at rt to afford the desired products in good yield.

The chloro derivatives **2a–l** were reacted with excess hydrazine hydrate (80%) for 6–8 h following the reported method [32,33,50] to afford the desired products **3a–l** (Scheme 1) as white solids, which were used directly in the next step.

The spectral data for compounds **2a–l** were previously reported by our group [32,33,50] and agreed with the reported data.

General Procedure for the Synthesis of **5a–i**

A solution of ethylacetoacetate **4** (1.0 mmol) and *N,N*-dimethylformamide dimethylacetal (1.2 mmol) was stirred for 5 min at rt and then 2,4-disubstituted-*s*-triazine derivatives **3a–i** (Scheme 1) (1.0 mmol) in ethanol-AcOH (2:1; 10 mL) were slowly added to the mixture. The reaction mixture was refluxed for 6–8 h. The progress of reactions was monitored by TLC (methanol- CHCl_3 ; 1:9 or ethylacetate-hexane; 1:1). After completion of the reaction, the solvent was evaporated under reduced pressure, and water (20 mL) was added to the residue, then extracted with ethylacetate (2×10 mL). The organic layer was successively washed with sodium carbonate solution and water and then dried with MgSO_4 . Evaporation of the solvent afforded target pyrazole derivatives **5a–i** (Schemes 2–4). The products were recrystallized from DCM-Petroleum ether 40–60.

1. Ethyl 1-(4,6-dimorpholino-1,3,5-triazin-2-yl)-5-methyl-1*H*-pyrazole-4-carboxylate, **5a**

Pale yellow solid in 81% yield, mp 158–159 °C. ^1H NMR (400 MHz, CDCl_3 , ppm) δ 1.34 (t, 3H, $J = 7.2$ Hz, CH_3), 2.92 (s, 3H, CH_3), 3.71. (brs, 8H, $\text{CH}_2\text{-N-CH}_2$), 3.82 (brs, 8H, $\text{CH}_2\text{-O-CH}_2$), 4.31 (q, 2H, $J = 7.2$ Hz, CH_2), 8.03 (s, 1H, $\text{CH}_{\text{pyrazole}}$); ^{13}C NMR (101 MHz, CDCl_3 , ppm) δ 14.1, 14.3, 43.9, 60.2, 66.7, 114.7, 143.0, 146.9, 163.5, 165.2. Anal. Calc. for $\text{C}_{18}\text{H}_{25}\text{N}_7\text{O}_4$ (403.44) C, 53.59; H, 6.25; N, 24.30. Found C, 53.35; H, 6.16; N, 24.52. HRMS-ESI (m/z) calculated for $[\text{M} + \text{H}]^+$ 404.44; found: 404.2034.

2. Ethyl 1-(4,6-di(piperidin-1-yl)-1,3,5-triazin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate, **5b**

Light brown solid in 80% yield, mp 134–136 °C. ¹H NMR (400 MHz, CDCl₃, ppm) δ 1.32 (t, 3H, *J* = 7.2 Hz, CH₃), 1.57 (brs, 8H, 4CH₂), 1.64 (brs, 4H, 2CH₂), 2.92 (s, 3H, CH₃), 3.76 (brs, 4H, CH₂-N-CH₂), 4.29 (q, 2H, *J* = 7.2 Hz, CH₂), 8.05 (s, 1H, CH_{pyrazole}); ¹³C NMR (100 MHz, CDCl₃, ppm) δ 13.9, 14.2, 24.7, 25.7, 44.5, 59.9, 114.3, 142.5, 146.7, 163.4, 163.6, 164.8. Anal. Calc. for C₂₀H₂₉N₇O₂ (399.50) C, 60.13; H, 7.32; N, 24.54. Found C, 60.34; H, 7.44; N, 24.71. HRMS-ESI (*m/z*) calculated for [M + H]⁺ 400.50; found: 400.2452.

3. Ethyl 5-methyl-1-(4-morpholino-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)-1H-pyrazole-4-carboxylate, **5c**

Light brown solid in 84% yield, mp 119–120 °C. ¹H NMR (400 MHz, CDCl₃, ppm) δ 1.33 (t, 3H, *J* = 7.2 Hz, CH₃), 1.50–1.65 (m, 6H, 3CH₂), 2.91 (s, 3H, CH₃), 3.69–3.77 (m, 12H, 6CH₂), 4.26 (q, 2H, *J* = 7.6 Hz, CH₂), 8.00 (s, 1H, CH_{pyrazole}); ¹³C NMR (101 MHz, CDCl₃, ppm) δ 14.0, 14.3, 24.6, 25.7, 43.7, 44.6, 60.0, 66.8, 114.4, 142.7, 146.7, 163.5, 164.6, 165.5. Anal. Calc. for C₁₉H₂₇N₇O₃ (401.47) C, 56.84; H, 6.78; N, 24.42. Found C, 56.66; H, 6.62; N, 24.67. HRMS-ESI (*m/z*) calculated for [M + H]⁺ 402.47; found: 402.2255.

4. Ethyl 5-methyl-1-(4-morpholino-6-(phenylamino)-1,3,5-triazin-2-yl)-1H-pyrazole-4-carboxylate, **5d**

Beige solid in 85% yield, mp 135–137 °C; ¹H NMR (400 MHz, CDCl₃, ppm) δ 1.33 (t, 3H, *J* = 7.2 Hz, CH₃), 2.97 (s, 3H, CH₃), 3.76 (brs, 4H, CH₂-N-CH₂), 3.85 (brs, 4H, CH₂-O-CH₂), 4.31 (q, 2H, *J* = 7.2 Hz, CH₂), 7.09 (t, 1H, *J* = 7.2 Hz, Ar-H), 7.33 (t, 2H, *J* = 7.2 Hz, Ar-H), 7.34 (brs, 1H, NH), 7.62 (t, 2H, *J* = 7.2 Hz, Ar-H), 8.09 (s, 1H, CH_{pyrazole}); ¹³C NMR (101 MHz, CDCl₃, ppm) δ 14.3, 44.2, 66.5, 99.9, 117.4, 120.8, 128.9, 138.2, 143.1, 147.2, 155.9, 163.4, 164.2. Anal. Calc. for C₂₀H₂₃N₇O₃ (409.45) C, 58.67; H, 5.66; N, 23.95. Found C, 58.90; H, 5.81; N, 24.19. HRMS-ESI (*m/z*) calculated for [M + H]⁺ 410.45; found: 410.2265.

5. Ethyl 5-methyl-1-(4-(phenylamino)-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)-1H-pyrazole-4-carboxylate, **5e**

Beige solid in 86% yield, 117–119 °C; ¹H NMR (400 MHz, CDCl₃, ppm) δ 1.39 (t, 3H, *J* = 7.2 Hz, CH₃), 1.67 (brs, 6H, 3CH₂), 2.90 (s, 3H, CH₃), 3.8 (brs, 4H, CH₂-N-CH₂), 4.31 (q, 2H, *J* = 7.2 Hz, CH₂), 7.09 (t, 1H, *J* = 7.2 Hz, Ar-H), 7.33 (t, 2H, *J* = 7.2 Hz, Ar-H), 7.34 (brs, 1H, NH), 7.62 (t, 2H, *J* = 7.2 Hz, Ar-H), 7.87 (brs, 1H, NH), 8.03 (s, 1H, CH_{pyrazole}); ¹³C NMR (101 MHz, CDCl₃, ppm) δ 14.3, 24.5, 25.7, 45.1, 60.2, 114.9, 120.2, 128.8, 138.2, 143.1, 147.2, 163.4, 164.2. Anal. Calc. for C₂₁H₂₅N₇O₂ (407.48): C, 61.90; H, 6.18; N, 24.06. Found C, 61.75; H, 6.23; N, 24.28. HRMS-ESI (*m/z*) calculated for [M + H]⁺ 408.48; found: 408.3255.

6. Ethyl 1-(4-((4-chlorophenyl)amino)-6-morpholino-1,3,5-triazin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate, **5f**

Pale yellow solid in 87% yield, mp 190–191 °C. ¹H NMR (400 MHz, CDCl₃, ppm) δ 1.35 (t, 3H, *J* = 7.2 Hz, CH₃), 2.96 (s, 3H, CH₃), 3.76 (t, 4H, *J* = 3.6 Hz, CH₂-N-CH₂), 3.85 (t, 4H, *J* = 4.4 Hz, CH₂-O-CH₂), 4.28 (q, 2H, *J* = 7.2 Hz, CH₂), 7.26 (d, 2H, *J* = 8.8 Hz, Ar-H), 7.47 (d, 2H, *J* = 8.8 Hz, Ar-H), 7.58 (brs, 1H, NH), 8.03 (s, 1H, CH_{pyrazole}); ¹³C NMR (101 MHz, CDCl₃, ppm) δ 14.3, 44.2, 60.2, 66.5, 115.1, 121.6, 128.9, 136.7, 143.2, 147.2, 163.3, 164.5, 165.2. Anal. Calc. for C₂₀H₂₂ClN₇O₃ (443.15) C, 54.12; H, 5.00; Cl, 7.99; N, 22.09. Found C, 54.30; H, 5.13; N, 22.31. HRMS-ESI (*m/z*) calculated for [M + H]⁺ 444.15; found: 444.1551.

7. Ethyl 1-(4-((4-chlorophenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate, **5g**

Beige solid in 89% yield, mp 140–142 °C; ¹H NMR (400 MHz, CDCl₃, ppm) δ 1.34 (t, 3H, *J* = 7.2 Hz, CH₃), 1.62 (brs, 4H, 2CH₂), 1.69 (brs, 2H, CH₂), 2.97 (s, 3H, CH₃), 3.80 (brs, 4H, CH₂-N-CH₂), 4.29 (q, 2H, *J* = 7.6 Hz, CH₂), 7.27 (dd, 2H, *J* = 3.6, 4.0 Hz, Ar-H), 7.38 (brs, 1H, N-H), 7.48 (d, 2H, *J* = 8.02, Ar-H), 8.03 (s, 1H, CH_{pyrazole}); ¹³C NMR (101 MHz, CDCl₃, ppm) δ: 14.1, 14.3, 24.5, 25.6, 45.1, 60.2, 114.8, 121.2, 128.3, 128.8, 137.0, 142.9, 147.1, 153.6, 157.6, 162.2, 163.4, 164.6. Anal. Calc. for C₂₁H₂₄ClN₇O₂ (441.92) C, 57.08; H, 5.47; N,

22.19. Found C, 57.21; H, 5.60; N, 22.34. HRMS-ESI (m/z) calculated for $[M + H]^+$ 442.92; found:442.9225.

8. Ethyl 1-(4-((4-methoxyphenyl)amino)-6-morpholino-1,3,5-triazin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate, **5h**

Beige solid in 82% yield, mp 158–160 °C; ^1H NMR (400 MHz, CDCl_3 , ppm) δ : 1.32 (t, 3H, $J = 7.2$ Hz, CH_3), 2.95 (s, 3H, CH_3), 3.75 (m, 4H, $\text{CH}_2\text{-N-CH}_2$), 3.78 (s, 3H, OCH_3), 3.82 (brs, 4H, $\text{CH}_2\text{-O-CH}_2$), 4.28 (q, 2H, $J = 7.6$ Hz, CH_2), 6.85 (d, 2H, $J = 9.2$ Hz, Ar-H), 7.43 (d, 2H, $J = 8.0$ Hz, Ar-H), 8.03 (s, 1H, CH-pyrazole), 8.10 (brs, 1H, NH); ^{13}C NMR (101 MHz, CDCl_3 , ppm) δ : 14.1, 14.7, 44.0, 55.4, 60.2, 66.51, 113.9, 114.9, 122.2, 142.9, 146.7, 163.5, 165.5, 176.1. Anal. Calc. for $\text{C}_{21}\text{H}_{25}\text{N}_7\text{O}_4$ (439.48): C, 57.39; H, 5.73; N, 22.31. Found C, 57.55; H, 5.86; N, 22.18. HRMS-ESI (m/z) calculated for $[M + H]^+$ 440.48; found:440.4556.

9. Ethyl 1-(4-((4-methoxyphenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)-5-methyl-1H-pyrazole-4-carboxylate, **5i**

Beige solid in 84% yield, mp 116–118 °C; ^1H NMR (400 MHz, CDCl_3 , ppm) δ 1.35 (t, 3H, $J = 7.2$ Hz, CH_3), 1.62 (brs, 4H, 2CH_2), 1.67 (brs, 2H, CH_2), 2.96 (s, 3H, CH_3), 3.77 (brs, 4H, $\text{CH}_2\text{-N-CH}_2$), 3.79 (s, 3H, OCH_3), 4.29 (q, 2H, $J = 7.2$ Hz, CH_2), 6.87 (d, 2H, $J = 8.6$ Hz, Ar-H), 7.43 (brs, 1H, NH), 7.46 (d, 2H, $J = 8.8$ Hz, Ar-H), 8.03 (s, 1H, CH-pyrazole); ^{13}C NMR (101 MHz, CDCl_3 , ppm) δ : 13.99, 14.04, 24.6, 25.7, 44.9, 55.4, 60.1, 113.9, 114.7, 122.1, 131.5, 142.8, 146.9, 162.0, 163.5, 165.5, 175.7. Anal. Calc. for $\text{C}_{22}\text{H}_{27}\text{N}_7\text{O}_3$ (437.50): C, 60.40; H, 6.22; N, 22.41. Found: C, 60.57; H, 6.35; N, 22.67. HRMS-ESI (m/z) calculated for $[M + H]^+$ 438.50; found:438.2255.

General Procedure for the Synthesis of s-Triazine Derivatives **7a–t**

A neat mixture of *N,N*-dimethylformamide dimethyl acetal (1.2 mmol) and 5,5-dimethyl-1,3-cyclohexadione **6a** or 1,3-cyclohexadione **6b** (Scheme 5) were mixed together and stirred for 10 min at rt. The hydrazine derivatives **3a–l** (1.0 mmol) in glacial acetic acid (10 mL) were slowly added to the mixture. The reaction mixture was refluxed for 8–12 h, and its progress was monitored by TLC (methanol- CHCl_3 ; 1:9 or ethyl acetate-hexane, 1:1). After completion of the reaction, the mixture was left to cool to rt and then poured into ice-cold water (50 mL). The aq. solution was extracted with ethyl acetate, washed 10% Na_2CO_3 solution, and water several times, then dried (Na_2SO_4) to afford the target products **7a–t** which were recrystallized from ethyl acetate to give the pure products (Scheme 5).

1. 1-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-6,6-dimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one, **7a**

Light brown solid in 80% yield, mp 196–198 °C. ^1H NMR (400 MHz, CDCl_3 , ppm) δ : 1.09 (s, 6H, 2CH_3), 2.39 (s, 2H, CH_2), 3.2 (s, 2H, CH_2), 3.73 (brs, 8H, $2\text{CH}_2\text{-N-CH}_2$), 3.83 (brs, 8H, $2\text{CH}_2\text{-O-CH}_2$), 8.08 (s, 1H, CH-pyrazole); ^{13}C NMR (101 MHz, CDCl_3 , ppm) δ : 28.5, 39.8, 43.6, 43.8, 51.8, 66.7, 120.9, 139.6, 151.5, 162.9, 164.6, 165.1, 193.0. Anal. Calc. for $\text{C}_{20}\text{H}_{27}\text{N}_7\text{O}_3$ (413.48) C, 58.10; H, 6.58; N, 23.71. Found C, 58.24; H, 6.71; N, 23.53. HRMS-ESI (m/z) calculated for $[M + H]^+$ 414.48; found: 414.2246.

2. 1-(4,6-Di(piperidin-1-yl)-1,3,5-triazin-2-yl)-6,6-dimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one, **7b**

Off-white solid in 83% yield, mp 176–177 °C. ^1H NMR (400 MHz, CDCl_3 , ppm) δ 1.08 (s, 6H, 2CH_3), 1.65 (brs, 12H, 6CH_2), 2.38 (s, 2H, CH_2), 3.22 (brs, 2H, CH_2), 3.81 (brs, 8H, $4\text{CH}_2\text{-CH}_2\text{-N-CH}_2$), 8.12 (s, 1H, CH-pyrazole); ^{13}C NMR (101 MHz, CDCl_3 , ppm) δ 24.6, 25.8, 28.5, 35.3, 40.0, 45.0, 51.8, 120.1, 139.6, 151.5, 162.3, 163.7, 193.1 (CO). Anal. Calc. for $\text{C}_{22}\text{H}_{31}\text{N}_7\text{O}$ (409.54) C, 64.52; H, 7.63; N, 23.94. Found C, C, 64.72; H, 7.81; N, 23.65. HRMS-ESI (m/z) calculated for $[M + H]^+$ 410.54; found: 410.2664.

3. 1-(4,6-Bis(phenylamino)-1,3,5-triazin-2-yl)-6,6-dimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one, **7c**

Light brown solid in 80% yield, mp 227–229 °C; ¹H NMR (400 MHz, CDCl₃, ppm) δ 1.09 (brs, 6H, 2CH₃), 2.35 (brs, 2H, CH₂), 3.06–3.34 (brs, 2H, CH₂), 7.16 (brs, 2H, Ar-H), 7.33 (brs, 4H, Ar-H), 7.56 (brs, 4H, Ar-H), 8.07 (s, 1H, CH_{pyrazole}), 8.19 (brs, 1H, NH); ¹³C NMR (101 MHz, CDCl₃, ppm) δ 28.5, 35.2, 39.6, 51.7, 114.0, 121.1, 123.4, 124.2, 129.2, 140.2, 152.3, 163.3, 175.2, 192.8 (CO). Anal. Calc. for C₂₄H₂₃N₇O (425.50): C, 67.75; H, 5.45; N, 23.04. Found: C, 67.98; H, 5.67; N, 23.30. HRMS-ESI (*m/z*) calculated for [M + H]⁺ 426.50; found: 426.2039.

4. 6,6-Dimethyl-1-(4-morpholino-6-(phenylamino)-1,3,5-triazin-2-yl)-1,5,6,7-tetrahydro-4H-indazol-4-one, **7d**

Off-white solid in 80% yield, mp 236–238 °C. ¹H NMR (400 MHz, CDCl₃, ppm) δ: 1.06 (s, 6H, 2CH₃), 2.39 (s, 2H, CH₂), 3.24 (s, 2H, CH₂), 3.77 (brs, 4H, 2CH₂; CH₂-N-CH₂), 3.88 (brs, 4H, 2CH₂; CH₂-O-CH₂), 7.10 (t, 1H, *J* = 7.6, Ar-H), 7.34 (t, 2H, *J* = 8.0, Ar-H), 7.7.53 (t, 2H, *J* = 7.6, Ar-H), 8.11 (s, 1H, CH_{pyrazole}); ¹³C NMR (101 MHz, CDCl₃, ppm) δ: 28.5, 35.3, 39.7, 44.2, 51.8, 66.5, 120.4, 121.1, 128.1, 138.1, 139.6, 141.7, 151.6, 162.7, 164.3, 165.2, 193.0 (CO). Anal. Calc. for C₂₂H₂₅N₇O₂ (419.49) C, 62.99; H, 6.01; N, 23.37. Found C, 62.73; H, 6.11; N, 23.54. HRMS-ESI (*m/z*) calculated for [M + H]⁺ 420.49; found:420.3225.

5. 6,6-Dimethyl-1-(4-(phenylamino)-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)-1,5,6,7-tetrahydro-4H-indazol-4-one, **7e**

Off-white solid in 86% yield, mp 230–232 °C. ¹H NMR (400 MHz, CDCl₃, ppm) δ 1.10 (s, 6H, 2CH₃), 1.64 (brs, 4H, 2CH₂), 1.71 (brs, 2H, CH₂), 2.39 (s, 2H, CH₂), 3.26 (s, 2H, CH₂), 3.84 (brs, 4H, 2CH₂; CH₂-N-CH₂), 7.06 (t, 1H, *J* = 7.6 Hz, Ar-H), 7.31 (t, 2H, *J* = 8.0, Ar-H), 7.35 (brs, 1H, NH), 7.56 (t, 2H, *J* = 7.6, Ar-H), 8.08 (s, 1H, CH_{pyrazole}); ¹³C NMR (101 MHz, CDCl₃, ppm) δ 24.6, 25.7, 28.5, 35.3, 39.7, 39.7, 45.1, 51.8, 120.1, 120.9, 123.7, 128.9, 138.3, 139.4, 151.6, 163.4, 164.7, 165.2, 193.1 (CO). Anal. Calc. for C₂₃H₂₇N₇O (417.52) C, 66.17; H, 6.52; N, 23.48. Found C, 66.32; H, 6.66; N, 23.21. HRMS-ESI (*m/z*) calculated for [M + H]⁺ 418.44; found:418.4225.

6. 1-(4-((4-Chlorophenyl)amino)-6-morpholino-1,3,5-triazin-2-yl)-6,6-dimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one, **7f**

Off-white solid in 81% yield, mp 237–239 °C. ¹H NMR (400 MHz, CDCl₃, ppm) δ 1.11 (s, 6H, 2CH₃), 2.41 (s, 2H, CH₂), 3.21 (brs, 2H, CH₂), 3.79 (t, 4H, *J* = 4.4 Hz, 2CH₂; CH₂-N-CH₂), 3.91 (brs, 4H, 2CH₂; CH₂-O-CH₂), 7.31 (d, 2H, *J* = 8.8, Ar-H), 7.52 (d, 2H, *J* = 8.8 Hz, Ar-H), 8.12 (s, 1H, CH, pyrazole); ¹³C NMR (101 MHz, CDCl₃, ppm) δ 28.5, 35.3, 39.7, 44.2, 51.7, 66.4, 121.4, 128.9, 140.1, 151.2, 162.7, 164.3, 176.0, 192.8 (CO). Anal. Calc. for C₂₂H₂₄ClN₇O₂ (453.93) C, 58.21; H, 5.33; N, 21.60. Found C, 58.43; H, 5.45; N, 21.83. HRMS-ESI (*m/z*) calculated for [M + H]⁺ 454.93; found:454.9522.

7. 1-(4-((4-Chlorophenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)-6,6-dimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one, **7g**

Off-white solid in 85% yield, mp 258–260 °C. ¹H NMR (400 MHz, CDCl₃, ppm) δ 1.09 (s, 6H, 2CH₃), 1.72 (brs, 6H, 3CH₂), 2.39 (s, 2H, CH₂), 3.19 (brs, 2H, CH₂), 3.87 (brs, 4H, 2CH₂; CH₂-N-CH₂), 7.24 (d, 2H, *J* = 8.4, Ar-H), 7.55 (d, 2H, *J* = 8.0, Ar-H), 8.12 (s, 1H, CH, pyrazole), 9.72 (brs, 1H, NH); ¹³C NMR (101 MHz, CDCl₃, ppm) δ: 24.3, 25.7, 28.5, 35.3, 39.6, 45.6, 51.7, 121.5, 128.9, 140.1, 151.6, 163.4, 164.7, 165.2, 176.0, 193.1 (CO). Anal. Calc. for C₂₃H₂₆ClN₇O (451.96) C, 61.12; H, 5.80; N, 21.69. Found C, 61.29; H, 5.91; N, 21.43. HRMS-ESI (*m/z*) calculated for [M + H]⁺ 452.96; found:452.8556.

8. 1-(4-((4-Methoxyphenyl)amino)-6-morpholino-1,3,5-triazin-2-yl)-6,6-dimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one, **7h**

Beige crystals for ethyl acetate in 81% yield, mp 190–192 °C; ¹H NMR (400 MHz, CDCl₃, ppm) δ 1.08 (s, 6H, 2CH₃), 2.35 (brs, 2H, CH₂), 3.22 (brs, 2H, CH₂), 3.75 (m, 7H,

OCH₃, 2CH₂, CH₂-N-CH₂), 3.84 (brs, 4H, 2CH₂; CH₂-O-CH₂), 6.84 (d, 2H, *J* = 8.8, Ar-H), 7.38 (brs, 2H, Ar-H), 7.85 (brs, 1H, NH), 8.01 (s, 1H, CH_{pyrazole}); ¹³C NMR (101 MHz, CDCl₃, ppm) δ 28.5, 35.3, 39.5, 44.2, 51.7, 55.5, 66.4, 113.9, 121.2, 122.1, 130.6, 139.6, 151.6, 156.3, 161.7, 163.3, 164.8, 176.0, 192.8 (CO). Anal. Calc. for C₂₃H₂₇N₇O₃ (449.52) C, 61.46; H, 6.05; N, 21.81. Found C, 61.67; H, 6.21; N, 22.01. HRMS-ESI (*m/z*) calculated for [M + H]⁺ 450.52; found: 450.2253.

9. 1-(4-((4-Methoxyphenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)-6,6-dimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one, **7i**

Beige crystals from ethyl acetate in 85% yield, mp 178–180 °C; ¹H NMR (400 MHz, CDCl₃, ppm) δ: 2.09 (brs, 2H, CH₂), 2.44 (brs, 2H, CH₂), 3.35 (brs, 2H, CH₂), 3.66 (brs, 8H, 4OCH₂-), 3.78 (brs, 8H, 4NCH₂-), 8.02 (s, 1H, CH_{pyrazole}); ¹³C NMR (101 MHz, CDCl₃, ppm) δ 25.7, 28.5, 35.2, 39.6, 45.2, 51.7, 55.4, 114.0, 121.1, 122.0, 130.6, 139.5, 151.9, 156.0, 163.3, 169.4, 175.2, 193.1 (CO). Anal. Calc. for C₂₄H₂₉N₇O₂ (447.24) C, 64.41; H, 6.53; N, 21.91. Found C, 64.23; H, 6.41; N, 22.013. HRMS-ESI (*m/z*) calculated for [M + H]⁺ 447.24; found: 448.2453.

10. 1-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-1,5,6,7-tetrahydro-4H-indazol-4-one, **7j**

White precipitate from ethyl acetate in 94% yield; mp 260–262 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.07 (brs, 2H, CH₂), 2.42 (brs, 2H, CH₂), 3.37 (brs, 2H, CH₂), 3.64 (brs, 8H, 4OCH₂-), 3.76 (brs, 8H, 4NCH₂-), 7.98 (s, 1H, CH_{pyrazole}); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 23.1, 25.0, 37.8, 43.5, 43.6, 66.8, 66.9, 121.2, 138.7, 152.8, 162.4, 164.6, 193.0; Anal. Calc. for C₁₈H₂₃N₇O₃ (385.43): C, 56.09; H, 6.02; N, 25.44. Found: C, 56.35; H, 6.19; N, 25.66; HRMS-ESI (*m/z*) calculated for [M + H]⁺ 386.43; found: 386.4432.

11. 1-(4,6-Di(piperidin-1-yl)-1,3,5-triazin-2-yl)-1,5,6,7-tetrahydro-4H-indazol-4-one, **7k**

Off-white precipitate from ethyl acetate in 92% yield; mp 199–200 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 1.51 (brs, 8H, 4CH₂), 1.62 (brs, 4H, 2CH₂), 2.05 (brs, 2H, CH₂), 2.42 (brs, 2H, CH₂), 3.28 (brs, 2H, CH₂), 3.73 (s, 8H, 4NCH₂-), 7.98 (s, 1H, CH_{pyrazole}); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 23.1, 24.2, 24.9, 25.2, 37.3, 43.8, 121.0, 138.3, 152.4, 162.5, 164.3, 193.0; Anal. Calc. for C₂₀H₂₇N₇O (381.48): C, 62.97; H, 7.13; N, 25.70. Found: C, 63.12; H, 7.30; N, 25.97; HRMS-ESI (*m/z*) calculated for [M + H]⁺ 382.48; found: 382.3455.

12. 1-(4-Morpholino-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)-1,5,6,7-tetrahydro-4H-indazol-4-one, **7l**

Off-white precipitate from ethyl acetate in 89% yield; mp 212–214 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 1.54 (brs, 4H, 2CH₂), 1.64 (brs, 2H, CH₂), 2.05–2.18 (m, 2H, CH₂), 2.42–2.46 (m, 2H, CH₂), 3.33 (brs, 2H, CH₂), 3.65 (brs, 4H, 2OCH₂), 3.76 (brs, 8H, 4NCH₂), 8.02 (s, 1H, CH_{pyrazole}); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 23.1, 24.1, 24.9, 25.2, 37.3, 44.3, 43.7, 65.9, 121.1, 138.5, 152.6, 162.5, 164.8, 193.0; Anal. Calc. for C₁₉H₂₅N₇O₂ (383.46): C, 59.51; H, 6.57; N, 25.57. Found: C, 59.73; H, 6.66; N, 25.80; HRMS-ESI (*m/z*) calculated for [M + H]⁺ 384.46; found: 384.4465.

13. 1-(4-Morpholino-6-(phenylamino)-1,3,5-triazin-2-yl)-1,5,6,7-tetrahydro-4H-indazol-4-one, **7m**

Off-white precipitate from ethyl acetate in 94% yield, mp 298–300 °C; ¹H NMR (400 MHz, CDCl₃) δ 2.26 (brs, 2H, CH₂), 2.61 (brs, 2H, CH₂), 3.36 (brs, 2H, CH₂-), 3.89 (brs, 4H, 2OCH₂), 3.97 (brs, 4H, 2 NCH₂), 7.28 (m, 2H, Ar-H), 7.39 (d, *J* = 8.0 Hz, 2H, Ar-H), 7.47 (d, *J* = 8.1 Hz, 2H, Ar-H), 7.47 (brs, 1H, NH), 8.13 (s, 1H, CH_{pyrazole}), 9.92 (s, 1H, NH); ¹³C NMR (101 MHz, CDCl₃) δ 22.7, 24.7, 37.1, 45.4, 66.2, 113.6, 116.4, 122.3, 123.6, 129.6, 134.7, 137.6, 154.4, 160.2, 161.3, 194.9; Anal. Calc. for C₂₀H₂₁N₇O₂ (391.44): C, 61.37; H, 5.41; N, 25.05. Found: C, 61.62; H, 5.52; N, 25.37; HRMS-ESI (*m/z*) calculated for [M + H]⁺ 392.44; found: 392.3455.

14. 1-(4-(Phenylamino)-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)-1,5,6,7-tetrahydro-4H-indazol-4-one, **7n**

White precipitate from ethyl acetate in 87% yield; mp 256–258 °C; ^1H NMR (400 MHz, DMSO- d_6) δ 1.161 (s, 4H, 2 CH₂), 1.68 (s, 2H, CH₂), 2.10 (brs, 2H, CH₂), 2.49 (brs, 2H, CH₂), 3.33 (brs, 2H, CH₂), 3.82 (s, 4H, 2NCH₂), 7.05 (m, 1H, Ar-H), 7.32 (t, J = 8.4 Hz, 2H, Ar-H), 7.80 (d, J = 8.8 Hz, 2H, Ar-H), 8.08 (s, 1H, CH_{pyrazole}), 10.05 (brs, 1H, NH); ^{13}C NMR (101 MHz, DMSO- d_6) δ 23.1, 24.1, 24.9, 25.4, 37.4, 44.3, 120.3, 121.2, 122.7, 128.6, 138.6, 139.3, 152.7, 162.5, 164.2, 193.0; Anal. Calc. for C₂₁H₂₃N₇O (389.46): C, 64.76; H, 5.41; N, 25.05. Found: C, 61.62; H, 5.95; N, 25.18; HRMS-ESI (m/z) calculated for [M + H]⁺ 390.46; found: 390.3545.

15. 1-(4-((4-Chlorophenyl)amino)-6-morpholino-1,3,5-triazin-2-yl)-1,5,6,7-tetrahydro-4H-indazol-4-one, **7o**

Off-white precipitate from ethyl acetate in 90% yield; mp 292–294 °C; ^1H NMR (400 MHz, DMSO- d_6) δ 2.01 (brs, 2H, CH₂), 2.43 (brs, 2H, CH₂), 3.35 (brs, 2H, CH₂), 3.70 (brs, 4H, 2OCH₂), 3.79 (brs, 4H, 2NCH₂-), 7.38 (d, J = 8.8 Hz, 2H, Ar-H), 7.77 (d, 2H, J = 8.8 Hz, Ar-H), 8.05 (s, 1H, CH_{pyrazole}), 10.23 (brs, 1H, NH); ^{13}C NMR (101 MHz, DMSO- d_6) δ 23.1, 25.0, 37.4, 43.8, 65.9, 111.9, 121.3, 121.8, 128.5, 138.2, 140.4, 152.9, 163.2, 164.5, 193.1; Anal. Calc. for C₂₀H₂₀ClN₇O₂ (425.88): C, 56.41; H, 4.73; N, 23.02. Found: C, 56.61; H, 4.87; Cl, 8.51; N, 23.20; HRMS-ESI (m/z) calculated for [M + H]⁺ 426.88; found: 427.1144.

16. 1-(4-((4-Bromophenyl)amino)-6-morpholino-1,3,5-triazin-2-yl)-1,5,6,7-tetrahydro-4H-indazol-4-one, **7p**

Off-white precipitate from ethyl acetate in 95% yield; mp 290–292 °C; ^1H NMR (400 MHz, CDCl₃) δ 2.26 (t, J = 6.2 Hz, 2H, CH₂), 2.63 (t, J = 6.6 Hz, 2H, CH₂), 3.38 (t, J = 6.4 Hz, 2H, CH₂), 3.88 (m, 4H, 2OCH₂-), 3.97 (m, 4H, 2NCH₂), 7.32 (d, J = 8.7 Hz, 2H, Ar-H), 7.51 (d, J = 8.3 Hz, 2H, Ar-H), 8.10 (s, 1H, CH_{pyrazole}), 9.95 (s, 1H, NH); ^{13}C NMR (101 MHz, CDCl₃) δ 22.5, 24.6, 37.0, 45.5, 66.0, 110.6, 113.5, 116.3, 119.2, 120.1, 123.5, 124.2, 132.4, 133.6, 142.2, 153.2, 154.8, 160.5, 161.0, 195.8; Anal. Calc. for C₂₀H₂₀BrN₇O₂ (470.33): C, 51.07; H, 4.29; N, 20.85. Found: C, 51.37; H, 4.41; N, 20.99; HRMS-ESI (m/z) calculated for [M + H]⁺ 471.33; found: 471.3255.

17. 1-(4-((4-Methoxyphenyl)amino)-6-morpholino-1,3,5-triazin-2-yl)-1,5,6,7-tetrahydro-4H-indazol-4-one, **7q**

Off-white precipitate from ethyl acetate in 88% yield; mp 254–256 °C; ^1H NMR (400 MHz, DMSO- d_6) δ 2.04 (brs, 2H, CH₂), 2.44 (brs, 2H, CH₂), 3.35 (brs, 2H, CH₂), 3.69 (brs, 4H, 2OCH₂), 3.74 (brs, 4H, 2NCH₂), 3.79 (s, 3H, OCH₃), 6.91 (d, J = 8.8 Hz, 2H, Ar-H), 7.62 (d, J = 8.6 Hz, 2H, Ar-H), 8.04 (s, 1H, CH_{pyrazole}), 10.00 (s, 1H, NH); ^{13}C NMR (101 MHz, DMSO- d_6) δ 23.1, 24.9, 37.8, 44.4, 55.2, 65.9, 113.9, 121.2, 121.7, 124.2, 138.5, 138.6, 152.8, 154.6, 164.9, 193.0; Anal. Calc. for C₂₁H₂₃N₇O₃ (421.46): C, 59.85; H, 5.50; N, 23.26. Found: C, 59.98; H, 5.66; N, 23.86; HRMS-ESI (m/z) calculated for [M + H]⁺ 422.46; found: 422.4566.

18. 1-(4-((4-Chlorophenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)-1,5,6,7-tetrahydro-4H-indazol-4-one, **7r**

White precipitate from ethyl acetate in 91% yield; mp. 265–267 °C; ^1H NMR (400 MHz, CDCl₃) δ 1.75–1.78 (d, J = 11.0 Hz, 6H, 3 CH₂), 2.30 (d, J = 6.6 Hz, 2H, CH₂), 2.63 (s, 2H, CH₂), 3.37 (s, 2H, CH₂), 3.88 (s, 4H, 2NCH₂-), 7.38 (s, 2H, Ar-H), 7.48 (s, 2H, Ar-H), 8.13 (s, 1H, CH_{pyrazole}), 10.21 (s, 1H, NH); ^{13}C NMR (101 MHz, CDCl₃) δ 22.86, 24.17, 25.29, 27.7, 37.30, 47.84, 111.52, 116.41, 124.39, 128.81, 133.79, 142.42, 154.16, 161.58, 162.63, 194.68; Anal. Calc. for C₂₁H₂₂ClN₇O (423.91): C, 59.50; H, 5.23; Cl, 8.36; N, 23.13, O, 3.77. Found: C, 59.66; H, 5.39; Cl, 8.57; N, 23.41, O, 3.99. (m/z) Calcd: 423.91; LC-MS [M + H]⁺ Found: 425.0025.

19. 1-(4-((4-Bromophenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)-1,5,6,7-tetrahydro-4H-indazol-4-one, **7s**

Off-white precipitate from ethyl acetate in 96% yield; mp. 280–283 °C; ¹H NMR (400 MHz, CDCl₃) δ 1.73 (td, *J* = 10.1, 9.6, 4.5 Hz, 6H, 3 CH₂), 2.24 (s, 2H, CH₂), 2.57 (s, 2H, CH₂), 3.36 (s, 2H, CH₂), 3.88 (s, 4H, 2NCH₂), 7.47 (s, 4H, Ar-H), 8.13 (s, 1H, CH_{pyrazole}), 9.95 (s, 1H, -NH); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 22.77, 24.61, 25.45, 27.41, 36.16, 43.88, 111.49, 117.25, 120.79, 122.24, 124.34, 130.17, 138.83, 148.84, 154.24, 161.45, 162.24, 165.31, 193.05; Anal. Calc. for C₂₁H₂₂BrN₇O (468.36): C, 53.85; H, 4.73; Br, 17.06, N, 20.93, O, 3.42; Found: C, 54.12; H, 4.89; Br, 17.39; N, 21.20, O, 3.55, (*m/z*) Calcd: 468.36; LC-MS [M + H]⁺ Found: 469.1269.

20. 1-(4-((4-Methoxyphenyl)amino)-6-(piperidin-1-yl)-1,3,5-triazin-2-yl)-1,5,6,7-tetrahydro-4H-indazol-4-one, **7t**

Off-white precipitate from ethyl acetate in 82% yield; mp. 233–235 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 1.47 (s, 4H, 2 CH₂), 1.66 (s, 2H, CH₂), 2.09 (s, 2H, CH₂), 2.34 (s, 2H, CH₂), 3.05 (2H, CH₂), 3.74 (s, 4H, 2NCH₂-), 3.81 (s, 3H, -OCH₃), 6.90 (s, 2H, Ar-H), 7.61 (s, 2H, Ar-H), 8.04 (s, 1H, CH_{pyrazole}), 10.06 (s, 1H, NH); ¹³C (101 MHz, DMSO-*d*₆) δ 20.80, 24.66, 25.82, 26.55, 37.26, 43.83, 55.72, 112.27, 120.79, 122.09, 123.00, 125.76, 133.16, 137.58, 153.21, 155.94, 163.01, 164.45, 166.42, 193.57; Anal. Calc. for C₂₂H₂₅N₇O₂ (419.49): C, 62.99; H, 6.01; N, 23.37, O, 7.63. Found: C, 63.15; H, 6.17; N, 23.52, O, 7.85. (*m/z*) Calcd: 419.49; LC-MS [M + H]⁺ Found: 420.2336.

2.2. Biology

2.2.1. Cell Culture

The parental MCF-7 (breast cancer), MDA-MB-231 (triple-negative breast cancer), U-87 MG (glioblastoma), A549 (non-small cell lung cancer), and PANC-1 (pancreatic cancer) cell lines and HDFs (human dermal fibroblasts) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). MCF-7 and A549 cells were cultured as an attached monolayer and maintained in RPMI 1640 medium (EuroClone, Milan, Italy) supplemented with 10% (*v/v*) heat-inactivated fetal bovine serum (FBS) (EuroClone, Milan, Italy), 1% penicillin-streptomycin (EuroClone, Milan, Italy), and 2 mM L-glutamine. MDA-MB-231 cells were cultured as an attached monolayer and maintained in MEM (EuroClone, Boston, MA, USA) supplemented with 10% (*v/v*) heat-inactivated fetal bovine serum (FBS) (EuroClone, Milan, Italy), 1% penicillin-streptomycin (EuroClone, Milan, Italy), and 2 mM L-glutamine. U-87, PANC-1 and HDFs were cultured as an attached monolayer and maintained in DMEM (EuroClone, Milan, Italy) supplemented with 10% (*v/v*) heat-inactivated FBS (EuroClone, Milan, Italy), 1% penicillin-streptomycin (EuroClone, Milan, Italy), and 2 mM L-glutamine. All cells were incubated at 37 °C in a 5% CO₂ tissue culture incubator (Mettler, Schwabach, Germany).

2.2.2. Cell Viability Assay (MTT)

To determine the IC₅₀ of the synthesized compounds **5a–i** and **7a–t** on the cell lines, an MTT assay was performed [51]. MDA-MB-231, MCF-7, and PANC-1 cells were seeded into 96-well plates at 8 × 10³ cells/well (Corning, New York, NY, USA), and U-87 and A549 cells and HDFs were seeded at 6.5 × 10³ cells/well. All cell lines were treated with concentrations of the tested compounds ranging from 0.5 to 500 µg/mL. Cells were then incubated at 37 °C in a 5% CO₂ incubator for 72 h, after which the old media was aspirated and the MTT assay salt (Bioworld, Visalia, CA, USA) in 100 µL of fresh media was added to each well. Next, plates were incubated at 37 °C for 3 h, then 50 µL of solubilization solution (DMSO) was added to each well to determine cell viability. The absorbance of the solution was measured at 560 nm using a Glomax plate reader (Promega, Madison, WI, USA).

2.2.3. EGFR Protein Kinase (PK) Inhibition

The EGFR-TK assay kit (ADP-GloTM kinase assay, Cat No. V9261, Promega, USA) was used to determine the inhibitory capacity of compounds **7d**, **7f** and **7c** against EGFR. The autophosphorylation percentage inhibition by the compounds was calculated using the following equation: $100 - \left[\frac{\text{Control}}{\text{Treated}} - \text{Control} \right]$ using the curves of percentage inhibition of 8 concentrations of each compound. IC₅₀ values were calculated using GraphPad Prism 7 software (Dotmatics, San Diego, CA, USA) [52].

2.2.4. PI3K/AKT/mTOR Downstream Signaling Pathway

ELISA kits of PI3K assay kit (Cat. No. MBS268899, Promega, Madison, MI, USA), AKT assay kit (Cat. No. MBS9511022, Promega, USA), and mTOR assay kit (Cat. No. LS-F21147, Promega, USA) were used to study the PI3k/AKT/mTOR downstream signaling pathway in MDA-MB-231 cells treated with **7d**, **7f** and **7c** at their IC₅₀ values or in untreated cells of the same line.

2.2.5. Apoptosis by Flow Cytometry

To study the growth inhibition of all the cell lines treated with **5a–i** and **7a–t**, the mechanism of apoptosis was determined by Annexin V/Propidium iodide (PI) stain using flow cytometry. Each cell line was seeded at 1×10^5 cells/well in 6-well plates and exposed to the IC₅₀ concentration of each compound for that specific cell line, as shown in Table 1. After 72 h, the cells were trypsinized using StemProTM AccutaseTM Cell Dissociation Reagent (GibcoTM, Inchinnan, UK). The collected cells were then washed with PBS. Next, the Annexin V/PI apoptosis kit (Invitrogen, Waltham, MA, USA) was used to stain the cell pellets, following the manufacturer's instructions. 10,000 events were counted by BD FACS CANTO II and analyzed using BD FACS DivaTM software version 7.0.

2.2.6. Gene Expression Analysis Using RT-qPCR

To further examine the apoptotic pathway, we assessed the gene expression of P53, Bax, Caspases-3, -8, and -9 as proapoptotic genes, Bcl-2 as the anti-apoptotic gene, and the downstream pathway of PI3K/AKT/mTOR. MDA-MB-231 cells were treated with compound **7f** at its IC₅₀ value for 48 h. After completing the treatment, cells were collected, and total RNA was extracted using the RNeasy[®] Mini Kit (Qiagen, Hilden, Germany). cDNA was then synthesized using 500 ng of RNA (*i*-Script cDNA synthesis kit, BioRad, Hercules, CA, USA). Finally, each RT-qPCR reaction was performed following routine work [53]. The Ct values were then collected to calculate the relative gene expression in all samples by normalization to the β -actin housekeeping gene [54,55].

2.2.7. CDOCKER Docking

CDOCKER is a CHARMM-based simulated annealing/molecular dynamics method that uses rigid receptors for docking [56]. The CDOCKER protocol includes the following steps: (i) A set of ligand conformations is generated using high-temperature molecular dynamics starting with different random seeds. (ii) Random orientations of the conformations are produced by translating the center of the ligand to a specified location within the receptor active site and performing a series of random rotations. (iii) A softened energy is calculated, and the orientation is kept if the energy is less than a specified threshold. This process continues until either the desired number of low-energy orientations is found, or the maximum number of poor orientations has been attempted. (iv) Each orientation is subjected to simulated annealing molecular dynamics. The temperature is heated to a high preset temperature and then cooled to the target temperature. (v) A final minimization of the ligand in the rigid receptor using non-softened potential is performed. For each final pose, the CHARMM energy (interaction energy plus ligand strain) and the interaction energy alone is calculated. The poses are sorted by CHARMM energy and the top-scoring (most negative, thus favorable to binding) poses are retained. To enhance performance and

shorten calculation times, a non-bond energy grid is used to calculate interaction energy rather than the full potential energy terms commonly used by CHARMM.

The following CDOCKER parameters were implemented in this study. A binding site sphere of 10.14 Å radius surrounding the copied co-crystallized ligand from the EGFR structure (PDB code: 6v6o) was implemented. The conformers of the starting ligands were energy-minimized and then heated to 1000 K over 1000 molecular dynamics steps to generate 50 starting random conformations for each ligand. Each random conformer was rotated 50 times within the binding pocket for subsequent energy refinement. The van der Waals energies of the resulting conformers/poses were examined and those of ≥ 300 kcal/mol were discarded. Surviving conformers/poses were subjected to a cycle of simulated annealing over 2000 heating steps to the targeted temperature of 700 K, followed by 5000 cooling steps to the targeted temperature of 300 K. The docked poses were energy-minimized to a gradient tolerance of zero kcal/mol/Å. A total of 599 poses were saved for subsequent scoring.

2.2.8. Scoring of Docked Poses


The highest-ranking docked conformers/poses generated by CDOCKER were scored using 9 scoring function: Jain [57,58], LigScore1, LigScore2 [59], PLP1, PLP2 [57], PMF, PMF04 [60,61], -CDOCKER Energy, and -CDOCKER Interaction Energy [56].

LigScore1 and LigScore2 scores were calculated using the CFF force field (version 1.02) and grid-based energies with a grid extension of 7.5 Å across the binding site. PMF scores were calculated using cutoff distances of 12.0 Å for carbon-carbon interactions and other atomic interactions, while PMF04 scores were calculated employing cutoff values of 6.0 and 9.0 Å for carbon-carbon interactions and other atomic interactions, respectively. -CDOCKER Energy and -CDOCKER Interaction Energy were calculated using the Momany-Rone ligand partial charge method. Docked conformers/poses were selected based on consensus among the 9 scoring functions [62,63]. The consensus function assigned a value of 1 for any molecular pose ranked within the highest 20% by the particular scoring function; otherwise, it was assigned a zero value (i.e., fit was within the lowest 80%). Subsequently, the consensus function summed up the scores for each molecular pose/conformer and ranked the molecular orientation. Docked poses of a particular ligand that achieved consensus among at least 8 scoring functions were selected and saved.

3. Results and Discussion


3.1. Chemistry

Hydrazino *s*-triazine derivatives **3a–l** required for this study were prepared following our reported method [32,33,50] (Scheme 1), where cyanuric chloride **1** was reacted with the first nucleophile at 0 °C in the presence of NaHCO₃ as a base and acetone–water as a solvent for 2 h. The second nucleophile was added at the same temperature in the presence of 1 equiv. of NaHCO₃ and the reaction was stirred at room temperature (rt) for 24 h. The products 2-chloro-4,6-disubstituted *s*-triazine derivatives **2a–l** were treated with hydrazine hydrate in ethanol under reflux for 6–8 h to afford the hydrazino derivatives **3a–l** [32,33,50], which were used directly in the next step without further purification.



Scheme 1. Synthesis of hydrazine-disubstituted *s*-triazine derivatives **3a-l**.

To optimize the reaction conditions for the incorporation of the pyrazole ring into the *s*-triazine scaffold, we started with the study of 4-hydrazinyl-6-morpholino-*N*-phenyl-1,3,5-triazin-2-amine **3d** as the model substrate (Table 1). Initially, ethylacetacetate **4** (1 equiv.) was reacted with neat DMF-DMA (1.2 equiv.) at rt for 5–10 min to generate the enaminedione intermediate I (Scheme 2), followed by the addition of 4-hydrazinyl-6-morpholino-*N*-phenyl-1,3,5-triazin-2-amine **3d** (1 equiv.) in 5% acetic acid in ethanol. The reaction mixture was refluxed for 4 h and monitored by TLC (*n*-hexane-ethylacetate, 1:1), which showed two products. The reaction did not promote at all with longer time (8 h) (Table 1, entries 1 and 2). The ¹H-NMR spectrum (Supporting information, Figure S1) showed the two products **5d** and **5d'** in a 1:1 ratio. Given that the yield of these products (**5d** and **5d'**, Scheme 2) was low, we hypothesized that this parameter could be affected by reaction time or acid loading in the medium.




Scheme 2. Proposed final products **5d'** and **5d** for the reaction of compound **3d** with ethylacetacetate and DMF-DMA.

Encouraged by this result, we focused on the solvent effect (Table 1). The reaction was repeated by altering the AcOH ratio (10%, 20% and 33.3%). Screening of AcOH loading revealed that the increasing percentage of AcOH was crucial, as the chemical yield of the cyclized product rather than the open form was enhanced. The optimal reaction condition was 33.3% AcOH, affording the final cyclized compound **5d** in 90% yield in 6 h (Entry 5), which increased to 95% after 8 h (Entry 6).

Table 1. Optimization of the cycloaddition reaction for the formation of the pyrazole derivatives.


Entry	Solvent	Time (h)	5d' %	5d %
1	5% AcOH-EtOH	4	50	50
2	5% AcOH-EtOH	8	50	50
3	10% AcOH-EtOH	8	40	60
4	20% AcOH-EtOH	6	~20	~80
5	AcOH-EtOH (1:2)	6	traces	~90
6	AcOH-EtOH (1:2)	8	traces	~95

The tentative synthetic reaction pathway is shown in Scheme 2. It comprises the initial formation of the enamine intermediate **I** in situ, followed by nucleophilic attack by the hydrazine derivative in the presence of AcOH to afford the final cyclized product. The hydrazine derivative **3d** could possibly attack the enamine intermediate **I** via two pathways (**A** or **B**). The enamine intermediate **I** is typically more reactive in bath **A** (**5d**) via initial addition-elimination amine-exchange of the dimethylamino group by the hydrazine derivative to afford the product **5d** through the open analogue **5d'** after removal of water molecule from the intermediate **II** [64,65]. This analogue of pyrazole derivative **5d** is more favor than its analogue in path **B** which first formation of the Schiff base (intermediate **III**) then Nu-attack to the enamine to afford the cyclized analogue **5d''** after removal of NEMe₂ (Scheme 3) [64,65].



Scheme 3. Proposed mechanism for the formation of pyrazole-s-triazine derivative **5d** as a model substrate.


Under the optimized conditions and configured the synthetic pathway, various hydrazine derivatives **3a–i**, including various heterocycles (morpholine and piperidine) and, substituted aryls employed in this reaction and furnished the products **5a–i**, as indicated in Scheme 4 in excellent yield. The spectral data for the synthesized compounds **5a–i** are provided in the supporting information, see Figures S2–S9).



Scheme 4. Synthesis of pyrazole-s-triazine derivatives **5a–i**.

To explore a cyclized 1,3-dicarbonyl compounds instead of ethylacetoacetate, for example, 5,5-dimethyl-1,3-cyclohexandione **6a** or 1,3-cyclohexadionone **6b** were employed in the reaction under the optimized reaction condition used for the synthesis of **5a–i** but did not afford the final compound **7**. In contrast, when the reaction was run in a neat AcOH, complete reaction occurred after 8–12 h, as shown by TLC (*n*-hexane-ethylacetate, 1:1). After completion of the reaction, the acidic solution was poured into ice-cold water and extracted with AcOEt or CHCl_3 . Next, the organic phase was washed with 10% Na_2CO_3 solution and NaCl solution and then dried over anhydrous MgSO_4 . The desired products **7a–t** (Scheme 5) were obtained after evaporation of the solvent.

The structures of all the products obtained were established by IR, NMR (^1H and ^{13}C), elemental analysis, and HRMS-ESI (Figures S10–S29 for the NMR spectrum and Figures S30–S38 for the HRMS). In addition, compound **7t** (CCDC No.: 2177427) was assigned based on single crystal X-ray diffraction analysis [66–69] (see Supporting Information).



Scheme 5. Synthesis of fused pyrazole-*s*-triazine derivatives **7a–t**.

3.2. Biology

3.2.1. Cytotoxicity

The anticancer activity of the pyrazolyl-*s*-triazine derivatives (**5a–i** and **7a–t**; Table 2) was studied in the following cell lines: human breast cancer (MCF-7 and MDA-MB-231); glioblastoma (U-87 MG); non-small cell lung cancer (A549); pancreatic cancer (PANC-1); and human dermal fibroblasts (HDFs). Most of the derivatives affected the viability of the six cancer cell lines, as determined by the MTT cell viability assay [51] (Table 2 and Figure 2). The most effective compounds were **7d**, **7f**, and **7c**. Of note, the substitution of the triazine ring had a marked impact on anticancer activity (Table 2). In most cases, compounds **5a–i** (carboxylate derivatives) showed lower activity than **7a–t** (5,5-dimethyl-1,3-cyclohexadione and 1,3-cyclohexadione derivatives). Moreover, 5,5-dimethyl-1,3-cyclohexadione *s*-triazine derivatives **7a–i** showed higher activity against most cancer cells compared with 1,3-cyclohexadione derivatives **7j–t**. In general, compounds with the aniline moiety exerted greater activity compared to those with a morpholine or piperidine ring. Interestingly, piperidine and morpholine can be considered to belong to the same family in some aspects of their synthetic chemistry. The presence of the piperidine moiety was detrimental for anticancer activity, as observed in compounds with both the piperidine and aniline ring attached to the triazine ring, compared to morpholine analogs. Compounds with two aniline moieties showed the highest activity (Table 2). Thus, **5d**, which contains morpholine and aniline, showed IC₅₀ values of 39.4 ± 1.9, 42.2 ± 3.4, 73.8 ± 21.0, 26.4 ± 2.7, 10.5 ± 2.4, and 33.4 ± 3.7 (μM) against MDA-MB-231, U-87 MG, PANC-1, A549, MCF-7 and HDFs, respectively. In contrast, compounds with two morpholine **5a**, two piperidine

5b, one morpholine and one piperidine **5c** and one piperidine and aniline **5e** showed lower activity, with higher IC_{50} values. In addition, compounds with substituted aniline (*p*-bromo-, *p*-chloro-, or *p*-methoxyaniline) exerted lower activity than unsubstituted aniline in this series of compounds. The same behavior was observed with series of compounds **7a–t** (Table 2).

Table 2. IC_{50} values of the tested compounds after the MTT assay showing variable responses of the treated cell lines with different specificity.





Compound	Anticancer Activity in Human Cancer Cells Lines					
	$IC_{50} \pm STDEV$ ($\mu M/mL$)					
	MDA-MB-231	U-87 MG	PANC-1	A549	MCF-7	HDFs
 5a	69.4 ± 2.5	65.4 ± 4.2	78.3 ± 7.7	74.6 ± 8.7	57.3 ± 6.2	74.6 ± 9.4
 5b	307.1 ± 64.8	355.2 ± 8.5	311.6 ± 30.4	503.4 ± 27.5	306.1 ± 47.6	351.2 ± 52.8
 5c	313.8 ± 13.9	840.4 ± 333.8	403.0 ± 47.8	404.0 ± 49.6	249.6 ± 26.7	356.2 ± 14.7
 5d	39.4 ± 1.9	42.2 ± 3.4	73.8 ± 21.0	26.4 ± 2.7	10.5 ± 2.4	33.4 ± 3.7

Table 2. Cont.





Compound	Anticancer Activity in Human Cancer Cells Lines					
	IC ₅₀ ± STDEV (µM/mL)					
	MDA-MB-231	U-87 MG	PANC-1	A549	MCF-7	HDFs
 <p>5e</p>	74.7 ± 10.3	193.8 ± 55.5	436.3 ± 59.9	608.4 ± 143.1	242.9 ± 87.9	140.6 ± 5.9
 <p>5f</p>	Not converged	10.4 ± 6.1	28.7 ± 7.7	Not converged	207.4 ± 9.5	11.5 ± 2.7
 <p>5g</p>	93.1 ± 7.7	206.2 ± 19.7	169.0 ± 10.9	202.5 ± 9.3	186.9 ± 34.8	155.5 ± 19.5
 <p>5h</p>	29.7 ± 1.8	76.7 ± 26.4	57.6 ± 9.8	592.1 ± 31.9	46.6 ± 11.1	126.1 ± 29.6

Table 2. Cont.





Compound	Anticancer Activity in Human Cancer Cells Lines					
	IC ₅₀ ± STDEV (µM/mL)					
	MDA-MB-231	U-87 MG	PANC-1	A549	MCF-7	HDFs
 <p>5i</p>	110.7 ± 20.8	330.5 ± 84.6	183.1 ± 30.2	249.4 ± 87.5	328.5 ± 92.6	170.3 ± 30.6
 <p>7a</p>	Not converged	Not converged	Not converged	Not converged	431.9 ± 58.5	Not converged
 <p>7b</p>	338.4 ± 114.5	292.8 ± 26.1	472.9 ± 73.3	228.5 ± 24.7	199.5 ± 13.2	3779.9 ± 627.3
 <p>7c</p>	28.2 ± 4.4	17.1 ± 4.2	16.4 ± 11.8	49.8 ± 4.5	15.7 ± 3.1	245.6 ± 22.8

Table 2. Cont.





Compound	Anticancer Activity in Human Cancer Cells Lines IC ₅₀ ± STDEV (µM/mL)					
	MDA-MB-231	U-87 MG	PANC-1	A549	MCF-7	HDFs
 7d	97.3 ± 9.3	10.9 ± 4.1	26.7 ± 8.3	12.4 ± 6.4	8.3 ± 2.1	38.9 ± 8.3
 7e	47.4 ± 13.2	73.1 ± 32.6	Not converged	89.8 ± 22.8	132.2 ± 28.0	47.4 ± 8.9
 7f	21.1 ± 2.6	41.6 ± 14.9	32.8 ± 12.3	52.0 ± 10.8	27.0 ± 11.0	65.0 ± 15.6
 7g	Not converged	Not converged	Not converged	Not converged	175.0 ± 93.6	4.2 ± 2.0

Table 2. Cont.





Compound	Anticancer Activity in Human Cancer Cells Lines IC ₅₀ ± STDEV (µM/mL)					
	MDA-MB-231	U-87 MG	PANC-1	A549	MCF-7	HDFs
 7h	402.2 ± 11.6	Not converged	37.7 ± 7.1	Not converged	206.2 ± 15.8	316.8 ± 23.4
 7i	567.9 ± 67.5	348.4 ± 126.6	939.3 ± 204.1	579.6 ± 285.1	25.8 ± 89.4	2922.4 ± 251.1
 7j	256.6 ± 51.1	Not converged	339.6 ± 67.2	507.7 ± 57.3	529.8 ± 50.3	1326.6 ± 128.2
 7k	437.5 ± 105.1	Not converged	515.9 ± 79.2	379.8 ± 90.2	290.2 ± 37.0	1337.7 ± 144.4

Table 2. Cont.





Compound	Anticancer Activity in Human Cancer Cells Lines IC ₅₀ ± STDEV (µM/mL)					
	MDA-MB-231	U-87 MG	PANC-1	A549	MCF-7	HDFs
 7l	Not converged	Not converged	Not converged	1744.1 ± 126.7	654.0 ± 144.2	638.7 ± 78.0
 7m	90.6 ± 13.0	74.7 ± 21.4	61.3 ± 16.9	43.4 ± 12.5	34.2 ± 4.1	117.0 ± 28.4
 7n	126.3 ± 41.9	185.4 ± 52.9	Not converged	92.9 ± 12.1	368.7 ± 42.1	189.5 ± 50.3
 7o	464.2 ± 105.7	51.4 ± 26.3	Not converged	85.7 ± 47.9	228.2 ± 100.0	54.5 ± 26.3

Table 2. Cont.









Compound	Anticancer Activity in Human Cancer Cells Lines					
	IC ₅₀ ± STDEV (µM/mL)					
	MDA-MB-231	U-87 MG	PANC-1	A549	MCF-7	HDFs
 <p>7p</p>	175.4 ± 64.0	345.1 ± 58.0	4.46 ± 2.3	Not converged	17.0 ± 56.3	93.8 ± 40.2
 <p>7q</p>	845.2 ± 205.0	Not converged	Not converged	179.4 ± 78.8	3430.9 ± 481.7	Not converged
 <p>7r</p>	16.1 ± 2.5	44.8 ± 3.5	60.0 ± 8.4	83.9 ± 12.1	2182.0 ± 221.7	20.7 ± 6.3
 <p>7s</p>	40.3 ± 9.3	71.5 ± 15.7	47.5 ± 2.6	18.6 ± 2.9	27.0 ± 4.7	74.7 ± 9.9

Table 2. Cont.

Compound	Anticancer Activity in Human Cancer Cells Lines					
	IC ₅₀ ± STDEV (µM/mL)					
	MDA-MB-231	U-87 MG	PANC-1	A549	MCF-7	HDFs
 7t	60.2 ± 12.7	269.0 ± 33.8	807.6 ± 165.3	12.4 ± 1.1	Not converged	122.9 ± 16.7
Doxorubicin	0.287 ± 0.035	0.057 ± 0.033	2.99 ± 1.56	0.278 ± 0.107	0.055 ± 0.0183	0.423 ± 0.270

Figure 2. Representative cell viability results used to calculate the IC₅₀ values for compounds 7d, 7f, and 7c.

In general, the IC₅₀ of **7d**, **7f**, and **7c** revealed a reduction in the viability of the cancer cell lines tested compared to the normal fibroblasts. Interestingly, there were some variations in the IC₅₀ values of the compounds in the distinct cancer cell lines. For instance, **7c** showed similar IC₅₀ values against MCF-7, U-87 MG, and PANC-1 cell lines (15.7–17.1 μM) while the values against the MDA-MB-231 and A549 cells were 28.2 and 49.8 μM, respectively. Compound **7d** was found to be more powerful against MCF-7, U-87 MG, and A549 cells, with IC₅₀ values of 8.3, 10.9, and 12.4 μM, respectively. On the other hand, the MDA-MB-231 cancer cell line showed resistance to **7d** compared to the HDFs. Compound **7f** was the least effective against the cancer cell lines. However, it showed selectivity against the MDA-MB-231 cell line compared to the other compounds and the IC₅₀ of other cell lines (Table 2, Figure 2).

3.2.2. EGFR Enzymatic Assay

The capacity of **7d**, **7f**, and **7c** to inhibit EGFR was tested (Table 3). Compounds **7d** and **7f** exhibited potent EGFR inhibitory activity, with IC₅₀ values of 59.24 and 70.3 nM, compared to Tamoxifen, with an IC₅₀ value of 69.1 nM. Compound **7c** showed moderate activity (IC₅₀ value of 81.6 nM).

Table 3. IC₅₀ values of the compounds tested in the EGFR-PK assay.

Compound	EGFR-PK Inhibition, IC ₅₀ [nM] ^{*,#}
7d	70.3 ± 1.34
7f	59.24 ± 1.16
7c	81.6 ± 1.67
Tamoxifen	69.1 ± 1.39

* Values are expressed as Mean ± SD of three independent replicates. # IC₅₀ values were calculated using sigmoidal non-linear regression curve fit of percentage inhibition against five concentrations of each compound.

3.2.3. PI3K/AKT/mTOR Downstream Signaling Pathway

To study the molecular target for the promising cytotoxicity of **7d**, **7f**, and **7c**, which showed the highest cytotoxic activity and promising EGFR inhibitory capacity, these compounds were tested against the PI3K, AKT, and mTOR downstream inhibition pathway. The PI3K/AKT/mTOR signaling cascade is important in many cellular processes, including growth and proliferation, apoptosis, survival, and metabolism, all of which contribute to tumor progression [70,71].

These compounds showed promising capacity to inhibit PI3K/AKT/mTOR (Table 4). In this regard, **7d** and **7f** exhibited remarkable PI3K/AKT/mTOR inhibitory activity by 0.66/0.82/0.8 and 0.35/0.56/0.66-fold, respectively, by inhibiting their concentrations to 4.39, 37.3, and 69.3 ng/mL in the **7d**-treatment, and to 2.39, 25.34, and 57.6 ng/mL in the **7f**-treatment compared to the untreated control; while compound **7c** did not show inhibitory activity compared to the control.

Table 4. Activity of the tested compounds **7d**, **7f**, and **7c**, against the EGFR downstream signaling pathway (PI3K/AKT/mTOR) in untreated and treated MDA-MB-231 cells.

Compound	PI3K (ng/mL)	AKT (ng/mL)	mToR (ng/mL)
Control	6.64 ± 0.15	45.39 ± 0.68	86.39 ± 2.1
7d	4.39 ± 0.16	37.3 ± 0.69	69.3 ± 1.98
7f	2.39 ± 0.12	25.34 ± 0.39	57.6 ± 1.23
7c	6.1 ± 0.36	42.6.3 ± 0.49	86.3 ± 1.67

Values are expressed as Mean ± SD of three independent replicates.

3.2.4. Apoptosis by Flow Cytometry

The results of the apoptosis assay showed significant induction of apoptosis by **7d**, **7f**, and **7c** in all the cancer cell lines compared to the normal cell line. In particular,

the greatest induction of apoptosis by these three compounds occurred in the MDA-MB-231 and PANC1 cancer cell lines. In this regard, they induced total apoptosis in MDA-MB-231 cells by 26.1%, 31.54%, and 17.2%, respectively, compared to 1.43% in the untreated control (Figures 3 and 4). Additionally, they induced total apoptosis in PANC1 cells by 31.7%, 30.4%, and 40.3%, respectively, compared to 11% in the untreated control (Figures 3 and S39). Furthermore, 7f showed more specific activation of apoptosis in the A549 cancer cell line (27.7% compared to 0.11% in control) compared to the other two compounds (Figures 3 and S39), and it induced total apoptosis in MCF-7 cells (21.53% compared to 0.67% in control). Histograms for Annexin V/PI staining in cancer cells were supported in the Supporting Information Figure S39. Results elucidated that cytotoxic activities in cancer cells were due to apoptosis rather than necrosis.




Figure 3. A representative diagram showing the percentage of apoptosis induction by 7d, 7f, and 7c in MDA-MB-231, MCF-7, U87 MG, A459, and PANC-1 cancer cell lines compared to HDFs. The results showed a higher percentage of apoptosis induced in all cancer cell lines compared to HDFs.




Figure 4. Annexin V/PI staining for apoptosis–necrosis assessment. Q1: Necrosis, Q2: Late apoptosis, Q3: Healthy cells, Q4: Early apoptosis in untreated and treated MDA-MB-231 cells with bar representation. * ($p \leq 0.05$) and ** ($p \leq 0.001$) significantly different using the unpaired test in GraphPad Prism.

3.2.5. Compound 7f Upregulated Pro-Apoptotic Genes and Downregulated Anti-Apoptotic Ones

To confirm the apoptosis-inducing activity of the compounds in MDA-MB-231 cells, we conducted gene expression analysis using RT-qPCR in both untreated and treated cells. As seen in Figure 5, treatment with compound 7f increased the expression of the following pro-apoptotic genes: a 3.8-fold increase in P53, a 2.8-fold increase in Bax, and a 6.7-, 3.06-, and 7-fold increase in caspases 3, 8, and 9, respectively. In contrast, this treatment caused a 0.17-fold decrease in the expression of the anti-apoptotic gene Bcl-2. In addition, this treatment induced a 0.61-, 0.32-, and 0.18-fold decrease in the PI3K/AKT/mTOR downstream pathway. These results regarding behavior of upregulating the proapoptotic genes and down-regulating the antiapoptotic gene agreed with previous literatures [50,72,73] on proving apoptosis induction in cancer cells. Apoptosis activity upon treatment with compound 7f, a derivative of pyrazolyl *s*-triazine moieties, was elucidated via EGFR inhibition and its downstreaming pathway of PI3K/AKT/mTOR.




Figure 5. Fold of change of apoptosis-related genes (A): Upregulated genes and (B): Downregulated genes in untreated and treated MDA-MB-231 cells with compound 7f. Values are expressed as Mean \pm SD of three independent replicates. Data were normalized using β -actin as house-keeping gene. Red dashed line represents the untreated control (Fold change = 1).

3.2.6. Molecular Docking Study

We implemented CDOCKER, with a binding site sphere of 10.14 Å radius (Figure 6). Docked poses (i.e., 599) generated by CDOCKER were scored by means of the following 9 scoring functions: Jain [57,58], LigScore1, LigScore2 [59], PLP1, PLP2 [57], PMF, PMF04 [60,61], -CDOCKER Energy, and -CDOCKER Interaction Energy [56].

We selected docked conformers/poses based on consensus among the 9 scoring functions [60,61]. The consensus function assigned a value of 1 for any molecular pose ranked within the highest 20% by the particular scoring function; otherwise, a zero value was assigned (i.e., the fit was within the lowest 80%). Docked poses of a particular ligand that achieved consensus among at least 8 scoring functions were selected.

The best-docked poses of 7d, 7f, and 7c interacted with several amino acids in the active site (Figure 6). Interactions included hydrogen bonding, and hydrophobic and electrostatic interactions. The three ligands showed slightly different binding modes in the active site (Figure 6), particularly 7d and 7f.

The central triazine ring of the three compounds is involved in hydrogen bonding with Lys745 (K745) and hydrophobic interactions with Val726 (V726). One terminal of the three compounds also participates in hydrophobic interactions and either hydrogen or electrostatic bonding with Arg841 (R841). The other terminals of the three compounds are

involved in several hydrophobic interactions with Leu718 (L718), Met790 (M790), Ala743 (A743), and Leu788 (L788). Of note, the binding site of the three compounds is enriched in basic amino acids (K745 and R841) and hydrophobic amino acids (V726, L718, M790, A743, and L788). All the binding poses in Figure 6 show a comparable number and type of interactions (i.e., consensus score ≥ 8), which are believed to play a significant role in the high affinity of these compounds.




Figure 6. (A) X-Ray structure of EGFR in complex with LN2380 ligand (PDB code: 6v60), with active binding site highlighted in pink. (B) The best-docked poses (pink) of the three tested compounds with consensus among at least 8 scoring functions. (C–E) show the best docking poses of **7d**, **7f**, and **7c** with the interacting amino acids in the active site. The carbon atoms of the ligands are depicted in pink. Hydrogen bonding, hydrophobic interactions, and electrostatic interactions are indicated by the dashed lines in green, light pink, and magenta, respectively. As shown in the figures, the three ligands are involved in a variety of interactions and have similar binding modes.

4. Conclusions

Here, we reported an easy one-pot procedure for the synthesis of pyrazole-*s*-triazine derivatives *via* the reaction of β -dicarbonyl compounds in the presence of DMF-DMA with 4,6-disubstituted 2-hydrazinyl-*s*-triazine in the presence of acetic acid. This method achieved a novel pyrazole and pyrazole-fused cycloalkanones in 80–95% yield and could find applications for the preparation of a variety of pyrazolo-*s*-triazine derivatives with biological activity of interest. Most of the tested compounds showed promising cytotoxicity against a panel of cancer cells and a safe profile against normal cells. Interestingly, compounds **7c**, **7d**, and **7f** induced apoptosis in MDA-MB-231 cells through the EGFR/PI3K/AKT/mTOR signaling pathway. Hence, these compounds emerge as potential target-oriented chemotherapeutic agents against breast cancer.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/pharmaceutics14081558/s1>, X-Ray determination of compound **7t**; Figures S1–S29: Selected NMR and MS spectrum data for the synthesized compounds **5a–i** and **7a–t**; Figures S30–S38: Selected HRMS spectrum data for some of the synthesized compounds **5** and **7** series; and Figure S39. Flow cytometric analysis (Annexin V-FTIC/PI assay).

Author Contributions: Conceptualization, A.E.-F., A.B. and F.A.; methodology, investigation, and formal analysis, I.S., A.S. and B.G.d.I.T.; software and X-ray diffraction analysis, M.H.; validation, methodology, and biological activity investigations, W.A., F.D., D.A.A., M.A.Z., M.M.H. and M.S.N.; resources, A.E.-F., A.B., M.H., M.S.N. and M.A.Z.; writing—original draft preparation, A.E.-F. and A.B.; writing—review and editing, A.E.-F., A.B., B.G.d.I.T. and F.A.; supervision, A.A., A.B. and A.E.-F.; funding acquisition, I.S. and A.B. All authors have read and agreed to the published version of the manuscript.

Funding: The authors would like to extend their sincere appreciation to the Researchers Supporting Project (RSP-2021/64), King Saud University, Riyadh, Saudi Arabia. The authors would like to acknowledge the support of Prince Sultan University for paying the Article Processing Charges (APC) of this publication.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors would like to extend their sincere appreciation to the Researchers Supporting Project (RSP-2021/64), King Saud University, Riyadh, Saudi Arabia. The authors would like to acknowledge the support of Prince Sultan University for paying the Article Processing Charges (APC) of this publication.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Szabó, G.; Fischer, J.; Kis-Varga, Á.; Gyires, K. New celecoxib derivatives as anti-inflammatory agents. *J. Med. Chem.* **2008**, *51*, 142–147. [[CrossRef](#)] [[PubMed](#)]
2. Popova, G.; Ladds, M.; Johansson, L.; Aljona, S.; Johanna, L.; Lars, S.; Sara, H.S.; Weixing, Q.; Hjalmar, G.; Neeraj, G.; et al. Optimization of tetrahydroindazoles as inhibitors of human dihydroorotate dehydrogenase and evaluation of their activity and in vitro metabolic stability. *J. Med. Chem.* **2020**, *63*, 3915–3934. [[CrossRef](#)] [[PubMed](#)]
3. Hammad, A.; Abutaleb, N.S.; Elsebaei, M.M.; Allison, B.N.; Mohamed, A.; Alsagher, A.; Jelan, A.A.; Abdelaziz, A.; Sammar, A.; Humaira, J.; et al. From phenylthiazoles to phenylpyrazoles: Broadening the antibacterial spectrum toward Carbapenem-resistant bacteria. *J. Med. Chem.* **2019**, *62*, 7998–8010. [[CrossRef](#)]
4. Kunitomo, J.; Yoshikawa, M.; Fushimi, M.; Kawada, A.; Quinn, J.F.; Oki, H.; Kokubo, H.; Kondo, M.; Nakashima, K.; Kamiguchi, N.; et al. Discovery of 1-[2-Fluoro-4-(1 H -pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1 H -pyrazol-5-yl)pyridazin-4(1 H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. *J. Med. Chem.* **2014**, *57*, 9627–9643. [[CrossRef](#)] [[PubMed](#)]
5. Salerno, S.; Barresi, E.; Amendola, G.; Berrino, E.; Milite, C.; Marini, A.M.; Da Settimo, F.; Novellino, E.; Supuran, C.T.; Cosconati, S.; et al. 4-Substituted benzenesulfonamides incorporating bi/tricyclic moieties act as potent and isoform-selective carbonic anhydrase II/IX inhibitors. *J. Med. Chem.* **2018**, *61*, 5765–5770. [[CrossRef](#)] [[PubMed](#)]
6. Prakash, O.; Hussain, K.; Kumar, R.; Wadhwa, D.; Sharma, C.; Aneja, K.R. Synthesis and antimicrobial evaluation of new 1,4-dihydro-4-pyrazolylpyridines and 4-pyrazolylpyridines. *Org. Med. Chem. Lett.* **2011**, *1*, 5. [[CrossRef](#)]
7. Li, M.; Zhao, B.X. Progress of the synthesis of condensed pyrazole derivatives (from 2010 to mid-2013). *Eur. J. Med. Chem.* **2014**, *85*, 311–340. [[CrossRef](#)] [[PubMed](#)]
8. Ningaiah, S.; Bhadraiah, U.K.; Doddaramappa, S.D.; Keshavamurthy, S.; Javarasetty, C. Novel pyrazole integrated 1,3,4-oxadiazoles: Synthesis, characterization and antimicrobial evaluation. *Bioorganic Med. Chem. Lett.* **2014**, *24*, 245–248. [[CrossRef](#)] [[PubMed](#)]
9. El-Sayed, M.A.A.; Abdel-Aziz, N.I.; Abdel-Aziz, A.A.M.; El-Azab, A.S.; Eltahir, K.E.H. Synthesis, biological evaluation and molecular modeling study of pyrazole and pyrazoline derivatives as selective COX-2 inhibitors and anti-inflammatory agents. Part 2. *Bioorganic Med. Chem.* **2012**, *20*, 3306–3316. [[CrossRef](#)]
10. Rathelot, P.; Azas, N.; El-Kashef, H.; Delmas, F.; Di Giorgio, C.; Timon-David, P.; Maldonado, J.; Vanelle, P. 1,3-Diphenylpyrazoles: Synthesis and antiparasitic activities of azomethine derivatives. *Eur. J. Med. Chem.* **2002**, *37*, 671–679. [[CrossRef](#)]
11. Abdel-Aziz, M.; Abu-Rahma, G.; Hassan, A.A. Synthesis of novel pyrazole derivatives and evaluation of their antidepressant and anticonvulsant activities. *Eur. J. Med. Chem.* **2009**, *44*, 3480–3487. [[CrossRef](#)]
12. Hashem, A.I.; Youssef, A.S.A.; Kandeel, K.A.; Abou-Elmagd, W.S.I. Conversion of some 2(3H)-furanones bearing a pyrazolyl group into other heterocyclic systems with a study of their antiviral activity. *Eur. J. Med. Chem.* **2007**, *42*, 934–939. [[CrossRef](#)]
13. Mert, S.; Kasimoğullari, R.; İça, T.; Çolak, F.; Altun, A.; Ok, S. Synthesis, structure-activity relationships, and in vitro antibacterial and antifungal activity evaluations of novel pyrazole carboxylic and dicarboxylic acid derivatives. *Eur. J. Med. Chem.* **2014**, *78*, 86–96. [[CrossRef](#)] [[PubMed](#)]

14. Lv, P.C.; Li, H.Q.; Sun, J.; Zhou, Y.; Zhu, H.L. Synthesis and biological evaluation of pyrazole derivatives containing thiourea skeleton as anticancer agents. *Bioorganic Med. Chem.* **2010**, *18*, 4606–4614. [[CrossRef](#)] [[PubMed](#)]
15. Khloya, P.; Celik, G.; Ram, S.; Vullo, D.; Supuran, C.T.; Sharma, P.K. 4-Functionalized 1,3-diarylpyrazoles bearing benzenesulfonamide moiety as selective potent inhibitors of the tumor associated carbonic anhydrase isoforms IX and XII. *Eur. J. Med. Chem.* **2014**, *76*, 284–290. [[CrossRef](#)] [[PubMed](#)]
16. Penning, T.D.; Talley, J.J.; Bertenshaw, S.R.; Carter, J.S.; Collins, P.W.; Docter, S.; Graneto, M.J.; Lee, L.F.; Malecha, J.W.; Miyashiro, J.M.; et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (sc-58635, celecoxib). *J. Med. Chem.* **1997**, *40*, 1347–1365. [[CrossRef](#)] [[PubMed](#)]
17. Terrett, N.K.; Bell, A.S.; Brown, D.; Ellis, P. Sildenafil (Viagra(TM)), a potent and selective inhibitor of type 5 CGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 1819–1824. [[CrossRef](#)]
18. Seltzman, H.H.; Carroll, F.I.; Burgess, J.P.; Wyrick, C.D.; Burch, D.F. Synthesis, spectral studies and tritiation of the cannabinoid antagonist SR141716A. *J. Chem. Soc. Chem. Commun.* **1995**, *15*, 1549–1550. [[CrossRef](#)]
19. Salem, M.E.; Darweesh, A.F.; Mekky, A.E.M.; Farag, A.M.; Elwahy, A.H.M. 2-Bromo-1-(1H-pyrazol-4-yl)ethanone: Versatile precursor for novel mono- and bis[pyrazolythiazoles]. *J. Heterocycl. Chem.* **2017**, *54*, 226–234. [[CrossRef](#)]
20. Rafique, R.; Khan, K.M.; Arshia; Chigurupati, S.; Wadood, A.; Rehman, A.U.; Salar, U.; Venugopal, V.; Shamim, S.; Taha, M.; et al. Synthesis, in vitro α -amylase inhibitory, and radicals (DPPH & ABTS) scavenging potentials of new N-sulfonohydrazide substituted indazoles. *Bioorg. Chem.* **2020**, *94*, 103410. [[CrossRef](#)] [[PubMed](#)]
21. Fustero, S.; Sánchez-Roselló, M.; Barrio, P.; Simón-Fuentes, A. From 2000 to mid-2010: A fruitful decade for the synthesis of pyrazoles. *Chem. Rev.* **2011**, *111*, 6984–7034. [[CrossRef](#)]
22. Dadiboyena, S.; Nefzi, A. Synthesis of functionalized tetrasubstituted pyrazolyl heterocycles—A review. *Eur. J. Med. Chem.* **2011**, *46*, 5258–5275. [[CrossRef](#)] [[PubMed](#)]
23. Janin, Y.L. Preparation and chemistry of 3/5-halogenopyrazoles. *Chem. Rev.* **2012**, *112*, 3924–3958. [[CrossRef](#)] [[PubMed](#)]
24. Alinezhad, H.; Tajbakhsh, M.; Zare, M. Catalyst-free one-pot synthesis of 1,4,5-trisubstituted pyrazoles in 2,2,2-trifluoroethanol. *J. Fluor. Chem.* **2011**, *132*, 995–1000. [[CrossRef](#)]
25. Kennedy, L.J. An expedient synthesis of regioisomeric pyrazole-fused cycloalkanones. *Synlett* **2008**, *4*, 600–604. [[CrossRef](#)]
26. Schenone, P.; Mosti, L.; Menozzi, G. Reaction of 2-dimethylaminomethylene-1,3-diones with dinucleophiles. I. Synthesis of 1,5-disubstituted 4-acylpyrazoles. *J. Heterocycl. Chem.* **1982**, *19*, 1355–1361. [[CrossRef](#)]
27. Menear, K.A.; Gomez, S.; Malagu, K.; Bailey, C.; Blackburn, K.; Cockcroft, X.-L.; Ewen, S.; Fundo, A.; Le Gall, A.; Hermann, G.; et al. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 5898–5901. [[CrossRef](#)]
28. Shah, D.R.; Modh, R.P.; Chikhaliya, K.H. Privileged s-triazines: Structure and pharmacological applications. *Future Med. Chem.* **2014**, *6*, 463–477. [[CrossRef](#)] [[PubMed](#)]
29. Liu, B. A Systematic review on antitumor agents with 1,3,5-triazines. *Med. Chem.* **2015**, *5*, 131–148. [[CrossRef](#)]
30. Perspicace, E.; Jouan-Hureauux, V.; Ragno, R.; Ballante, F.; Sartini, S.; La Motta, C.; Da Settimo, F.; Chen, B.; Kirsch, G.; Schneider, S.; et al. Design, synthesis and biological evaluation of new classes of thieno[3,2-d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). *Eur. J. Med. Chem.* **2013**, *63*, 765–781. [[CrossRef](#)]
31. Alhameed, R.A.; Almarhoon, Z.; Sholkamy, E.N.; Khan, S.A.; Albericio, F.; El-faham, A. Novel 4,6-Disubstituted s-Triazin-2-yl Amino Acid Derivatives as Promising Antifungal Agents. *J. Fungi* **2020**, *6*, 237–251. [[CrossRef](#)] [[PubMed](#)]
32. Al Rasheed, H.; Malebari, A.M.; Dahlous, K.; Fayne, D.; El-Faham, A. Synthesis, anti-proliferative activity, and molecular docking study of new series of 1,3,5-triazine Schiff base derivatives. *Molecules* **2020**, *25*, 4065. [[CrossRef](#)] [[PubMed](#)]
33. Al Rasheed, H.; Dahlous, K.; Sharma, A.; Sholkamy, E.; El-Faham, A.; de la Torre, B.G.; Albericio, F. Barbiturate-and thiobarbiturate-based s-triazine hydrazone derivatives with promising antiproliferative activities. *ACS Omega* **2020**, *5*, 15805–15811. [[CrossRef](#)]
34. De la Hoz, A.; Diaz-Ortiz, A.; Elguero, J.; Martinez, L.; Moreno, A.; Sanchez-Migallon, A. Solvent-free preparation of trispyrazolyl-1,3,5-triazines. *Tetrahedron* **2001**, *57*, 4403. [[CrossRef](#)]
35. de la Hoz, A.; Sánchez-Migallón, A. Green synthesis of 1,3,5-triazines with applications in supramolecular and materials chemistry. *Targets Heterocycl. Syst.* **2016**, *20*, 139–173. [[CrossRef](#)]
36. Ayyangar, N.R.; Lahoti, R.J.; Lugade, A.G.; Oti, S.R. Synthesis of monoazo disperse dyes from 5-amino-3-methyl-1-(3',5'-disubstituted) s-triazinylpyrazoles and a study of their visible absorption and dyeing properties. *J. Soc. Dye. Colour.* **1986**, *102*, 176–181. [[CrossRef](#)]
37. Mikhaylichenko, S.N.; Patel, S.M.; Dalili, S.; Chesnyuk, A.A.; Zaplishny, V.N. Synthesis and structure of new 1,3,5-triazine-pyrazole derivatives. *Tetrahedron Lett.* **2009**, *50*, 2505–2508. [[CrossRef](#)]
38. Sharma, A.; Ghabbour, H.; Khan, S.T.; de la Torre, B.G.; Albericio, F.; El-Faham, A. Novel pyrazolyl-s-triazine derivatives, molecular structure and antimicrobial activity. *J. Mol. Struct.* **2017**, *1145*, 244–253. [[CrossRef](#)]
39. Farooq, M.; Sharma, A.; Almarhoon, Z.; Al-Dhfyhan, A.; El-Faham, A.; Taha, N.A.; Wadaan, M.A.M.; Torre, B.; Albericio, F. Design and synthesis of mono- and di-pyrazolyl-s-triazine derivatives, their anticancer profile in human cancer cell lines, and in vivo toxicity in zebrafish embryos. *Bioorg. Chem.* **2019**, *87*, 457–464. [[CrossRef](#)]

40. Keldsen, N.; Havsteen, H.; Vergote, I.; Bertelsen, K.; Jakobsen, A. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: A phase II study. *Gynecol. Oncol.* **2003**, *88*, 118–122. [[CrossRef](#)]
41. Kim, E.S. Enasidenib: First Global Approval. *Drugs* **2017**, *77*, 1705–1711. [[CrossRef](#)] [[PubMed](#)]
42. Shor, R.E.; Dai, J.; Lee, S.; Pisarsky, L.; Matei, I.; Lucotti, S.; Lyden, D.; Bissell, M.J.; Ghajar, C.M. The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings. *Mol. Oncol.* **2022**, *16*, 130–147. [[CrossRef](#)] [[PubMed](#)]
43. Bhat, H.R.; Masih, A.; Shakya, A.; Ghosh, S.K.; Singh, U.P. Design, synthesis, anticancer, antibacterial, and antifungal evaluation of 4-aminoquinoline-1,3,5-triazine derivatives. *J. Heterocycl. Chem.* **2019**, *57*, 390–399. [[CrossRef](#)]
44. Raghu, M.S.; Kumar, C.; Prashanth, M.K.; Kumar, K.Y. Novel 1,3,5-triazine-based pyrazole derivatives as potential antitumor agents and EGFR kinase inhibitors: Synthesis, cytotoxicity, DNA binding, molecular docking and DFT studies. *New J. Chem.* **2021**, *45*, 13909–13924. [[CrossRef](#)]
45. Van-Dort, M.E.; Galbán, S.; Wang, H.; Sebolt-Leopold, J.; Whitehead, C.; Hong, H.; Rehemtulla, A.; Ross, B.D. Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor. *Bioorganic Med. Chem.* **2015**, *23*, 1386–1394. [[CrossRef](#)] [[PubMed](#)]
46. Wang, Y.; Tortorella, M. Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review. *Eur. J. Med. Chem.* **2022**, *228*, 114039. [[CrossRef](#)]
47. Zoncu, R.; Efeyan, A.; Sabatini, D.M. MTOR: From growth signal integration to cancer, diabetes and ageing. *Nat. Rev. Mol. Cell Biol.* **2011**, *12*, 21–35. [[CrossRef](#)]
48. Beaufiles, F.; Cmiljanovic, N.; Cmiljanovic, V.; Bohnacker, T.; Melone, A.; Marone, R.; Jackson, E.; Zhang, X.; Sele, A.; Borsari, C.; et al. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class i PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. *J. Med. Chem.* **2017**, *60*, 7524–7538. [[CrossRef](#)] [[PubMed](#)]
49. Hu, J.; Zhang, Y.; Tan, N.; Lu, Y.; Guo, P.; Huang, Z. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR. *Bioorganic Med. Chem.* **2021**, *32*, 115997. [[CrossRef](#)]
50. Shawish, I.; Barakat, A.; Aldalbahi, A.; Malebari, A.; Nafie, M.S.; Bekhit, A.A.; Albohy, A.; Khan, A.; Ul-Haq, Z.; Haukka, M.; et al. Synthesis and antiproliferative activity of a new series of mono- and bis(dimethylpyrazolyl)-s-triazine derivatives targeting EGFR/PI3K/AKT/mTOR signaling cascades. *ACS Omega* **2022**, *7*, 24858–24870. [[CrossRef](#)]
51. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods* **1983**, *65*, 55–63. [[CrossRef](#)]
52. Hisham, M.; Youssif, B.; Osman, E.; Hayallah, A.M.; Abdel-Aziz, M. Synthesis and biological evaluation of novel xanthine derivatives as potential apoptotic antitumor agents. *Eur. J. Med. Chem.* **2019**, *176*, 117–128. [[CrossRef](#)] [[PubMed](#)]
53. Nafie, M.S.; Arafa, K.; Sedky, N.K.; Alakhdar, A.A.; Arafa, R.K. Triaryl dicationic DNA minor-groove binders with antioxidant activity display cytotoxicity and induce apoptosis in breast cancer: Dicationic compounds as anticancer and apoptotic inducing agents. *Chem.-Biol. Interact.* **2020**, *324*, 109087. [[CrossRef](#)] [[PubMed](#)]
54. Sarhan, A.; Boraie, A.; Barakat, A.; Nafie, M.S. Discovery of hydrazide-based pyridazino[4,5-b]indole scaffold as a new phosphoinositide 3-kinase (PI3K) inhibitor for breast cancer therapy. *RSC Adv.* **2020**, *10*, 19534–19541. [[CrossRef](#)] [[PubMed](#)]
55. Nafie, M.S.; Mahgoub, S.; Amer, A.M. Antimicrobial and antiproliferative activities of novel synthesized 6-(quinolin-2-ylthio)pyridine derivatives with molecular docking study as multi-targeted JAK2/STAT3 inhibitors. *Chem. Biol. Drug Des.* **2021**, *97*, 553–564. [[CrossRef](#)] [[PubMed](#)]
56. Wu, G.; Robertson, D.H.; Iii, C.; Vieth, M. Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMM-based MD docking algorithm. *J. Comput. Chem.* **2003**, *24*, 1549–1562. [[CrossRef](#)]
57. Toviwek, B.; Gleeson, D.; Gleeson, M. QM/MM and molecular dynamics investigation of the mechanism of covalent inhibition of TAK1 kinase. *Org. Biomol. Chem.* **2021**, *19*, 1412–1425. [[CrossRef](#)]
58. Jain, A.N. Scoring noncovalent protein-ligand interactions: A continuous differentiable function tuned to compute binding affinities. *J. Comput.-Aided Mol. Des.* **1996**, *10*, 427–440. [[CrossRef](#)]
59. Venkatachalam, C.M.; Jiang, X.; Oldfield, T.; Waldman, M. LigandFit: A novel method for the shape-directed rapid docking of ligands to protein active sites. *J. Mol. Graph. Model.* **2003**, *21*, 289–307. [[CrossRef](#)]
60. Muegge, I.; Martin, Y.C. A general and fast scoring function for protein-ligand interactions: A simplified potential approach. *J. Med. Chem.* **1999**, *42*, 791–804. [[CrossRef](#)]
61. Muegge, I. A knowledge-based scoring function for protein-ligand interactions: Probing the reference state. *Perspect. Drug Discov. Des.* **2002**, *20*, 99–114. [[CrossRef](#)]
62. Clark, R.D.; Strizhev, A.; Leonard, J.M.; Blake, J.F.; Matthew, J.B. Consensus scoring for ligand/protein interactions. *J. Mol. Graph. Model.* **2002**, *20*, 281–295. [[CrossRef](#)]
63. Feher, M. Consensus scoring for protein-ligand interactions. *Drug Discov. Today.* **2006**, *11*, 421–428. [[CrossRef](#)] [[PubMed](#)]
64. Ullrich, T.; Dersch, C.M.; Rothman, R.B.; Jacobson, A.E.; Rice, K.C. Derivatives of 17-(2-methylallyl)-substituted noroxymorphone: Variation of the delta address and its effects on affinity and selectivity for the delta opioid receptor. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 2883–2885. [[CrossRef](#)]
65. Olivera, R.; SanMartin, R.; Dominguez, E. Dibenzoxepino [4, 5-d] pyrazoles: A facile approach via the Ullmann-ether reaction. *Tetrahedron Lett.* **2000**, *41*, 4353–4356. [[CrossRef](#)]

66. Rikagu Oxford Diffraction. *CrysAlisPro*; Agilent Technologies Inc.: Oxfordshire, UK, 2018.
67. Sheldrick, G.M. SHELXT-Integrated Space-Group and Crystal-Structure Determination. *Acta Crystallogr. Sect. A Found. Adv.* **2015**, *71*, 3–8. [[CrossRef](#)]
68. Sheldrick, G.M. Crystal Structure Refinement with SHELXL. *Acta Crystallogr. Sect. C Struct. Chem.* **2015**, *71*, 3–8. [[CrossRef](#)]
69. Hübschle, C.B.; Sheldrick, G.M.; Dittrich, B. *ShelXle*: A Qt graphical user interface for SHELXL. *J. Appl. Crystallogr.* **2011**, *44*, 1281–1284. [[CrossRef](#)]
70. Hassan, B.; Akcakanat, A.; Holder, A.M.; Meric-Bernstam, F. Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway. *Surg. Oncol. Clin. N. Am.* **2013**, *22*, 641–664. [[CrossRef](#)]
71. Lee, J.X.; Loh, K.; Yap, Y.S. PI3K/Akt/mTOR inhibitors in breast cancer. *Cancer Biol. Med.* **2015**, *12*, 342–354. [[CrossRef](#)]
72. ElZahabi, H.; Nafie, M.S.; Osman, D.; Elghazawy, N.H.; Soliman, D.H.; EL-Helby, A.; Arafa, R.K. Design, synthesis and evaluation of new quinazolin-4-one derivatives as apoptotic enhancers and autophagy inhibitors with potent antitumor activity. *Eur. J. Med. Chem.* **2021**, *222*, 113609. [[CrossRef](#)] [[PubMed](#)]
73. Nafie, M.S.; Khodair, A.; Hassan, H.; El-Fadeal, N.; Bogari, H.; Elhady, S.S.; Ahmed, S.A. Evaluation of 2-thioxoimidazolidin-4-one derivatives as potent anti-cancer agents through apoptosis induction and antioxidant activation: In vitro and in vivo Approaches. *Molecules* **2021**, *27*, 83. [[CrossRef](#)]